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Abstract
Low-dose-rate prostate brachytherapy involves the implantation of tiny radioactive seeds into
the prostate to treat prostate cancer. The current standard post-implant imaging modality
is computed tomography (CT). On CT images, the radioactive seeds can be distinctively
localized but delineation of the prostate and surrounding soft tissue is poor. Magnetic
resonance imaging (MRI) provides better prostate and soft tissue delineation, but seed
localization is difficult. To aid with seed localization, MRI markers with encapsulated
contrast agent that provide positive-contrast on MRI images (Sirius MRI markers; C4
Imaging, Houston, TX) have been proposed to be placed adjacent to the negative-contrast
seeds. This dissertation describes the development of the Sirius MRI markers for prostate
post-implant dosimetry.
First, I compared the dose-volume histogram and other dosimetry parameters generated
by MIM Symphony (a brachytherapy treatment planning system that allow the use of MRI
images for treatment planning; MIM Software Inc., Cleveland, OH) and VariSeed (a widely
used brachytherapy treatment planning system; Varian Medical Systems, Inc., Palo Alto,
CA), and found the dosimetry between both brachytherapy treatment planning systems to
be comparable. To gain more insight into the MRI contrast characteristics of the Sirius
MRI markers, I measured the Sirius MRI marker contrast agent’s spin-lattice and spin-spin
relaxivities, and studied the relaxation characteristics’ dependence on MRI field strength,
temperature, and orientation.
From the Sirius MRI marker’s contrast agent relaxation characteristics, I systematically
studied the effect of varying MRI scan parameters such as flip angle, number of excitations,
vi
bandwidth, field of view, slice thickness, and encoding steps, on the Sirius MRI markers’
signal and contrast, as well as image noise, artifact and scan time. On patients implanted
with Sirius MRI markers, I evaluated the visibility of the Sirius MRI markers and image
artifacts. Lastly, I semi-automated the localization of markers and seeds to more enable the
efficient incorporation of Sirius MRI markers as part of the clinical post-implant workflow.
Ultimately, the Sirius MRI markers may change the paradigm from CT-based to MRI-
based post-implant dosimetry, for a more accurate understanding of dose-response relation-
ships in patients undergoing low dose rate prostate brachytherapy.
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1.1 Dissertation Scope and Organization
The overall narrative and organization of this dissertation is outlined in Figure 1.1. In
Chapter 1, the background and motivation of this dissertation work are provided. The
prostate is surrounded by structures involved in bowel, urinary and sexual functions (Section
1.2). A pathology of the prostate is prostate cancer, whereby the treatment options include
radiation (Section 1.3). In this dissertation, the focus is on a form of radiation therapy,
namely low-dose-rate prostate brachytherapy or prostate implants (Section 1.4). To assess the
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Figure 1.1: The scope of this dissertation is highlighted (dark green box) within the overall
framework of prostate implants for the treatment of prostate cancer. The organization of
this dissertation is denoted by the chapter numbers under each topic.
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efficacy of a prostate implant for local control of prostate cancer and reduced normal tissue
complications, post-implant assessment of dose-volume histogram parameters is performed
on pelvic images acquired after the implant (Section 1.5). On these images, seed locations
are used to calculate dose, while physician-drawn soft tissue contours are used to calculate
volume (Section 1.5.3). The post-implant imaging options are mainly computed tomography
(CT) and magnetic resonance imaging (MRI) (Section 1.6). On CT images, the contrast
between the seeds and prostate tissue is high, but soft tissue contrast is low (Section 1.6.1).
On MRI images, soft tissue contrast is high, but the seeds appear as dark voids that are
difficult to localize because the dark voids are also generated by spacers and needle tracks
(Section 1.6.2). With these two imaging modalities, the possible options for imaging-based
post-implant dosimetric assessment are CT-only assessment, CT-MRI fusion assessment and
MRI-only assessment. For CT-only assessment, the main problem is the high interobserver
variation in contouring of the prostate and surrounding structures (Sections 1.6.1 and
5.1.1). For CT-MRI fusion-based assessment, the main problem is the greater uncertainties
introduced by the fusion process (Sections 1.6.2 and 5.1.2). MRI-only assessment is not
routinely used in clinical practice (Section 5.1.3) because seed localization on MRI images is
difficult.
A potential solution to enable MRI-only post-implant assessment is to use easily-localized
encapsulated contrast agent markers (Sirius MRI markers; C4 Imaging, Houston, TX) in
between the seeds (Section 1.7). In this dissertation, I present four more components
necessary to complete the workflow for incorporating Sirius MRI markers into an MRI-only
post-implant dosimetry setting.
1. To enable MRI-only post-implant dosimetry using Sirius MRI markers, a treatment
planning system (TPS) that will allow for marker-based post-implant dosimetry is
needed. The MIM Symphony TPS (MIM Software Inc., Cleveland, OH) was identified
as a viable alternative to the VariSeed TPS (Varian Medical Systems, Inc., Palo
Alto, CA), which is a TPS widely-used around the world and was used for prostate
implant procedures at our institution at the time. In Chapter 2, I benchmarked the
MIM Symphony TPS against the VariSeed TPS by evaluating the calculations of
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dose (Section 2.4.1), volume (Sections 2.4.2 and 2.4.3.1) and dose-volume histogram
parameters (Section 2.4.3.2) of both TPS.
2. To use the Sirius MRI markers, we need to understand the intrinsic relaxation char-
acteristics of the contrast agent that will be encapsulated in Sirius MRI markers. In
Chapter 3, I evaluated the C4 contrast agent’s spin-lattice and spin-spin relaxation
times at varying concentrations to obtain the relaxivities for different field strengths
(Section 3.4.1), orientations (Section 3.4.2) and temperatures (Section 3.4.3).
3. After determining the relaxation times of the C4 contrast agent, we need to identify
a suitable pulse sequence that enhances the encapsulated contrast agent markers.
Chapter 4 describes the effects on the Sirius MRI markers’ signal-to-noise ratio, scan
time and resolution in a prostate phantom due to variations in user-adjustable pulse
sequence parameters, such as flip angle (Section 4.4.1), number of excitations (Section
4.4.2), bandwidth (Section 4.4.3), field of view (Section 4.4.4), slice thickness (Section
4.4.5) and encoding steps (Section 4.4.6). Subsequently, Chapter 5 describes our
initial experience visualizing Sirius MRI markers in patients using the pulse sequence
parameter ranges determined in phantom, as well as the unique challenges of using
Sirius MRI markers in the clinical setting.
4. To enable higher efficiency in clinics, the observer-dependent manual seed localization
on MRI images needs to be automated. In Chapter 6, I present two approaches of
marker-based seed localization algorithms. One approach is to find the Sirius MRI
markers and directly extrapolate the seed locations, while the other approach is to
register marker locations on MRI images to the marker and seed configurations available
in the pre-implant template.
Finally, in Chapter 7, I propose future investigations and conclude with a discussion of the
future implications. MRI-only post-implant dosimetry may eventually enable accurate and
consistent characterization of the dose distribution, ultimately allowing for better correlation
of the dose received by the prostate and critical structures around the prostate to clinical
outcomes. Someday, we may have higher confidence in the prediction of under- or over-dosed
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Figure 1.2: Location of the prostate and surrounding critical structures. Reprinted from
Frank H. Netter. Atlas of Human Anatomy. 5th ed. Philadelphia: W. B. Saunders Co.,
2011.3
areas in the prostate for enhanced tumor control, as well as the prediction and management
of complications from the dose to normal tissues surrounding the prostate.
1.2 Prostate and Surrounding Structures
The prostate is a walnut-shaped gland located in the pelvis that secretes sperm-nourishing
fluid.1 Typical prostate sizes range from 20 cc to 110 cc and the length ranges from 3 cm to
6 cm.2 The prostate is surrounded by a dense fibrous capsule containing nerves and veins
coated with a fibrous prostatic sheath.1 The superior aspect of the prostate is the base while
the inferior aspect is the apex.1 The prostate can be divided into three zones, namely the
anterior muscular zone, the central zone and the peripheral zone.1
Several structures involved in bowel, urinary and sexual functions are in the vicinity of
the prostate (Figure 1.2). The functions of these structures are interwoven with the side
effects of prostate treatments.∗
∗See Section 1.4 for a discussion of the side effects of prostate implants.
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Bowel function The rectum and anal canal are the final parts of the alimentary tract
posterior to the prostate that stores feces.1 The angle between the rectum and anal canal is
maintained by the puborectalis muscle at roughly 80◦ for fecal continence and straightened
during defecation.1 The rectum is directly posterior to the prostate.4 The Denonvilliers’
fascia are fibromuscular layers that separate the prostate from the rectum to about 4.6 cm
away.2
Urinary function The bladder is a hollow muscular sac superior to the prostate that
temporarily stores urine.1 The bladder neck’s muscle fibers are continuous with the prostate
base’s fibromuscular tissue.1 The urethra is a thin muscular tube running through the
prostate that transports urine from the bladder’s internal urethral orifice to the penis tip’s
external urethral orifice.1 The prostatic urethra length ranges from 3 cm to 6 cm with a 29◦
bend at about 68% of the prostate length from the bladder neck.2 The internal urethral
sphincter is an involuntary muscle directly inferior to the bladder that prohibits urine release
and prevents ejaculate from entering the bladder.1 The external urethral sphincter is a
voluntary muscle directly inferior to the prostate that keeps the urethra compressed to
maintain urinary continence.1
Sexual function The penis is a roughly-cylindrical organ inferior to the prostate that
contains erectile tissue that fills with blood to harden and contains the external urethral
orifice.1 The urethra, previously mentioned in terms of urinary function, is also involved
in sexual function, namely to deliver semen.1 The penile bulb is the base of the penis and
is covered by the bulbospongiosus muscle that compresses the penile bulb to discharge
remaining urine or semen.1 The seminal vesicles are elongated glands posterosuperior to
the prostate between the bladder and rectum that secretes a thick alkaline fluid to form
the semen.1 The neurovascular bundle is a network of nerves and blood vessels running
along the posterolateral surface of the prostate that supports erectile function. The internal
pudendal artery is the main blood vessel with branches supplying blood for erectile function.1
If the internal pudendal artery is obstructed, the penis will receive less blood, subsequently
impairing erections.5
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1.3 Prostate Cancer Incidence and Treatments
According to estimates by the American Cancer Society, prostate cancer has the highest
incidence of cancer (180 890 projected new cases in 2016†) and second highest mortality rate
(26 120 projected deaths in 2016‡) in men, apart from skin cancer.6 According to the National
Comprehensive Cancer Network (NCCN) guidelines,7 initial diagnosis of prostate cancer
can be made through digital rectal examination (DRE), blood test for the prostate-specific
antigen (PSA), and transrectal-ultrasound (TRUS) guided biopsy to evaluate the Gleason
score (indicates cancer aggressiveness). Next, depending on the patient’s life expectancy and
symptomatic status, cancer staging can be done with imaging, including bone scan, pelvic
CT or MRI.7 The patients are then stratified into risk groups (very low, low, intermediate,
high, very high and metastatic), depending on the American Joint Committee on Cancer
(AJCC) clinical stage, biopsy Gleason score, and PSA.7 The risk groups predict biochemical
failure-free survival (using PSA as a prostate cancer indicator),8 thereby forming the basis
for treatment recommendations.7
After risk group stratification, the next course-of-action is either monitoring (active
surveillance or inactive observation) or treatment of the prostate cancer. Treatment options
include radiation therapy (brachytherapy, external beam photon and proton radiation therapy
and radiopharmaceutical therapy), surgery (radical prostatectomy and pelvic lymph node
dissection), hormone/androgen deprivation therapy, immunotherapy, and chemotherapy.7
1.4 Prostate Implant Indications and Outcomes
Prostate implants, also known as low-dose-rate (LDR) prostate brachytherapy, is of par-
ticular interest for the treatment of early-stage prostate cancer. From the definition by
the International Commission of Radiation Units and Measurements (ICRU) Report 38,9
LDR brachytherapy refers to radiation dose rates of 0.4 Gy/h to 2 Gy/h while high-dose-
†Incidence estimates by the American Cancer Society used data collected from the Surveillance, Epidemi-
ology and End Results (SEER) program at the National Cancer Institute (NCI), National Program of Cancer
Registries (NPCR) at the Centers for Disease Control and Prevention (CDC), and the North American
Association of Central Cancer Registries (NAACCR).6
‡Mortality estimates by the American Cancer Society used data collected from the National Center for
Health Statistics (NCHS).6
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rate (HDR) brachytherapy refers to dose rates > 12 Gy/h.§ According to the American
Brachytherapy Society consensus guidelines, prostate implants are indicated as monotherapy
for low-risk patients, supplemented with external beam radiotherapy for high risk patients,
and case-dependent for intermediate risk patients.10 Notably, prostate implant as the primary
treatment for low-risk patients is accepted by the NCI, NCCN, American Cancer Society
(ACR), American Urologic Association (AUA), American Society for Radiation Oncology
(ASTRO), American College of Radiology (ACR), European Society for Therapeutic Ra-
diology and Oncology (ESTRO), European Association of Urology (EAU), and European
Organization for Research and Treatment of Cancer (EORTC).7,10–12
During a prostate implant procedure, numerous small radioactive seeds of a given isotope
are permanently implanted into the prostate to deliver localized radiation (Figure 1.3). The
seeds may be loose or stranded, and are deposited under transrectal ultrasound (TRUS) and
template guidance. As the radioactive isotope decays, the seeds release radiation, damaging
the integrity of the nearby cells.14
Common radioisotopes used for the seeds are Iodine-125, Palladium-103, and Cesium-
131.¶ The seeds typically have a length of 4.5 mm and diameter of 0.8 mm, but the specific
geometries depend on the seed manufacturer.15
Prostate brachytherapy is associated with high survival (biochemical failure-free sur-
vival, metastatasis-free survival, prostate cancer specific survival, overall survival) and low
complications (urinary continence, lack of urinary and bowel bother, preservation of sexual
and hormonal function) at low costs (Figure 1.4).16 Hayes et al.17 reported that in low-risk
patients, compared to radical prostatectomy and intensity modulated radiation therapy
(IMRT, a form of external beam radiation therapy that delivers highly conformal dose to
the prostate), LDR brachytherapy has the lowest cost and highest quality-adjusted life
expectancy. Shah et al.18 reported no significant differences in survival outcomes among LDR
brachytherapy, HDR brachytherapy and IMRT, while LDR brachytherapy cost signficantly
less to Medicare and health care institutions ($9938 for LDR brachytherapy, $17 514 for
HDR brachytherapy with 4 fractions and $29 356 for IMRT).
§Gray (Gy) is the SI unit for ionizing radiation dose. 1 Gy = 1 J/kg
¶See Section 2.1.1 for more information about radioactive sources used for prostate implants.
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Figure 1.3: Permanent prostate brachytherapy involves placing many radioactive seeds
within the prostate to treat prostate cancer. During the procedure, an ultrasound probe is
placed in the rectum to help guide the placement of seeds. The seeds emit radiation that
dissipates over a few weeks or months. Reprinted from Permanent prostate brachytherapy.
url: http://www.mayoclinic.org/tests- procedures/prostate- brachytherapy/
multimedia/permanent-prostate-brachytherapy/img-20008710.13
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Figure 1.4: Radar chart representing the value framework for prostate implants. The radar
chart tool can be used to visualize multiple outcome and costing metrics simultaneously.
The chart allows direct visualization of the 6-month complications, 4-year patient-reported
outcomes, 10-year survival, and time-driven activity-based costing provider costs at 1 year
after implantation. The red line visually connects each numerical outcome or cost value on
each axis. The blue dotted line represents the baseline Expanded Prostate Cancer Index
Composite (EPIC) scores before prostate implant treatment. Reprinted from N. G. Thaker,
T. J. Pugh, U. Mahmood, S. Choi, T. E. Spinks, N. E. Martin, T. T. Sio, R. J. Kudchadker,
R. S. Kaplan, D. A. Kuban, D. A. Swanson, P. F. Orio, M. J. Zelefsky, B. W. Cox,
L. Potters, T. A. Buchholz, T. W. Feeley, and S. J. Frank. “Defining the value framework
for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-
based costing”. In: Brachytherapy (2016)16 (license number: 3876101241296).
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Since prostate implants are associated with low morbidity,10 consideration of quality-of-
life after treatment is imperative. Quality-of-life can be impacted by bowel, urinary and
sexual complications, given the adjacency of critical structures described in Section 1.2. For
instance, Holmes et al.2 reported a mean distance from individual seeds of 1.6 cm to the
urethra, and 2.3 cm to the rectum. The Expanded Prostate Cancer Index Composite (EPIC)
survey questionnaire can be used to evaluate bowel, urinary and sexual complications. Acute
urinary complications, such as urethral stricture, urinary bother, urinary retention, urinary
incontinence and painful urination, are common but usually resolve within a year.19,20 Also
common are bowel complications, such as frequent bowel movements, diarrhea, constipation
and rectal fistula.20,21 Sexual complications include erectile dysfunction, blood in semen,
pain during orgasm and alteration in orgasm intensity.5,20,22,23
1.5 Prostate Implant General Workflow
The prostate implant workflow can be broken down into three stages: pre-implant, implant
and post-implant.
1.5.1 Pre-implant
Prior to the implant, transrectal ultrasound (TRUS) is the common imaging modality used
to assess any potential interference of the needle and pubic arch, as well as obtain images
to generate a treatment plan. The physician typically contours the prostate and critical
structures (rectum, bladder and urethra) on the TRUS images. The physicist or dosimetrist
then plan the seed locations such that the prescribed dose (typically 110 Gy to 160 Gy for
monotherapy, depending on the isotope10) is delivered to as much of the prostate volume
while minimizing dose to critical structures. For instance, Figure 1.5 shows a pre-implant
plan with a peripheral loading pattern whereby seeds are loaded mostly at the periphery of
the prostate, thus reducing dose to the central prostatic urethra.
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(a) Peripheral loading pattern
(b) Needle configuration
Figure 1.5: (a) The peripheral loading pattern involves needle placement avoiding the
urethra running through the center of the prostate. (b) The needles contain seeds (green)
with spacers in between and have different configurations depending on placement of that
particular needle in the prostate.
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1.5.2 Implant
Current prostate brachytherapy implantation procedures are performed via the transperineal
approach using TRUS and template guidance for needle insertion by the physician.24
Depending on the prostate size and radionuclide, the number of seeds implanted typically
ranges from 50 to 150.25
This dissertation focuses on the uncertainties related to the evaluation of the quality
of the implant. However, the quality of the implant itself can be affected by several
uncertainties that are independent of the evaluation process. When reporting outcomes of
the evaluation of implant quality, the factors affecting implant quality should be isolated.
Explored below are the uncertainties that can affect the quality of the implant, such as
varying institution standards, differences due to seed manufacturer, individual variations
of the physician performing the implant, the manual process of needle insertion into the
prostate, inhomogeneity of disease distribution, and seed migration.
Institution standards Apart from variations of individual physicians, at a higher level,
different institutions have varying implant techniques.26,27 For instance, some institutions
may use more activity per implant and others may have more generous prostatic margins to
address extraprostatic disease, resulting in variations in glandular coverage or uniformity due
to varying prioritization of biological endpoints.26 Nomograms, used for outcome prediction
during treatment selection, may not predict the recurrence after prostate implants depending
on institutional variability.28
Seed manufacturer Even for the same radioisotope of the same source strength, different
seed manufacturer have variations in dosimetry and visibility on images.29‖
Physician implant performance Physician training and experience in performing im-
plants affects the deposited seed distributed and consequently, the implant quality. For
instance, some physicians tend to include a more generous margin due to their experience in
external beam radiation therapy.27
‖See Section 2.1.1 for further details on the impact of seed type on prostate D90 and MRI susceptibility
artifacts.
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Manual needle insertion There is intrinsic variation of inserting needles manually, with a
large contributing factor due to prostate movement during needle insertion. The pre-implant
plan assumed dose distribution based on perfectly parallel strands.
Disease distribution An implant with adequate dose coverage of the prostate would not
be sufficient if there was undetected microscopic disease at the periphery or outside the
prostate.30,31 Similarly, inadequate dose coverage of the prostate may still be of good quality
for disease control if the underdosing occured in non-diseased regions in the prostate.30
Seed migration In rare occasions, during needle insertion of the seeds, perforation of
the urethra or blood vessels may lead to seed loss via the urethra or seed migration until
lodged in small pulmonary vessels.32 Migration is especially common with the use of free
seeds. Kunos et al.33 reported that out of 12 524 seeds implanted in their study cohort, 249
seeds migrated, with 68 to the lungs. The use of stranded seeds compared to loose seeds
is associated with a lower incidence of seed migration to the lungs.34 Al-Qaisieh et al.34
observed no evidence of seed migration to the lungs in any of the 238 patients implanted
with stranded seeds (RAPIDStrand; GE Healthcare, Arlington Heights, IL).
1.5.3 Post-implant
The patient undergoes a CT pelvic exam typically within 60 days after the implant (usually
either on the day of the implant or approximately 30 days later).10 The physician contours
the prostate and critical structures on the CT images. Next, the seed locations are roughly
identified with an automated software built-in to the TPS and manually-corrected. The seed
locations and structure contours allow for an assessment of the dose delivered to the prostate
and critical structures. To assess implant quality, the current standard is to evaluate dose
volume histogram (DVH) parameters and isodose line coverage of anatomy on post-implant
images. Figure 1.6 illustrates the interpretation of a DVH. Several limits are in place for
DVH parameters in LDR prostate brachytherapy, such as D90 (minimum dose covering 90%
of the structure), V100 (volume receiving 100% of the prescribed dose), and V150 (volume
receiving 150% of the prescribed dose). Lastly, the patient undergoes follow-up care whereby
14
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Figure 1.6: A dose-volume histogram (DVH) is a histogram with radiation dose on the
x-axis and structure volume on the y-axis. The red line is the DVH for the prostate, as
displayed using the VariSeed treatment planning system. The prostate D90 is the minimum
dose covering 90% of the prostate volume, as denoted by the blue arrow. The prostate V100
is the volume of the prostate receiving 100% of the prescribed dose, as denoted by the blue
box (in this case, the prescription dose was 125 Gy for a Pd-103 implant, as indicated at the
top right corner).
the PSA is checked frequently.
The post-implant dosimetric assessment is important for several reasons. Firstly, for
day-of-implant dosimetric evaluations, sub-standard implant quality may indicate corrective
therapy, such as bringing the patient back to the operating room for implantation of additional
seeds into the prostate. Another value of post-implant dosimetry is to serve as feedback to
the prostate brachytherapy team for future improvements, such as the physician’s needle
insertion techniques and the physicist’s or dosimetrist’s seed loading pattern strategies. Last
but most certainly not least, through implant quality evaluation, institutions may better
determine dose-response relationships and better establish the correlation between implant
strategies to tumor control and normal tissue complications. Implant quality has been linked
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to biochemical control and survival.30,35–39
Apart from the uncertainties affecting implant quality described in Section 1.5.2, there
are also uncertainties associated with implant quality evaluation. Given the importance
of implant quality evaluation, we need to be cognizant of the uncertainties of implant
quality evaluation, which can affect the perceived implant quality and subsequent clinical
management. Since dose is continuously delivered until the radioisotope decays to a negligible
level, and patient anatomy during this entire course of treatment is highly variable, the
post-implant images only represent a snapshot of the dose distribution in the prostate and
nearby critical structures.
Some uncertainties stemming from using DVH parameters obtained from post-implant
images as a surrogate for implant quality are elucidated below. These uncertainties of implant
quality evaluation stem from varying amounts of bladder and rectal filling, prostate edema,
physician contouring, the dose calculation formalism, brachytherapy TPS, and post-implant
imaging modality. Of these factors, this dissertation focuses on the uncertainties of implant
quality evaluation due to the brachytherapy TPS and post-implant imaging modality.
Bladder and rectal filling at the time of post-implant imaging The bladder and
rectum are expandable muscular structures to accommodate storage of urine and feces. The
filling of the bladder and rectum changes the location of the prostate in relation to other
critical structures. Post-implant imaging at a certain time only offers a snapshot in time of
the dose distribution to critical structures nearby.
Extent and resolution of prostate edema Prostate swelling due to needle-induced
trauma increases the perceived prostate volume.40 Edema also affect the interseed distance
and subsequent dose coverage.41 Furthermore, edema affects seed fixity, leading to seed
migration.32 The extent of prostate edema affects the seed distribution in the prostate
and in relation to critical structures. Post-implant dosimetric evaluation on the day of the
implant results in edema-derived dosimetric errors compared to evaluation at a later stage
(optimal timing is 16± 4 days for Pd-103 implants and 30± 7 days for I-125 implants).10
Edema can be assessed by comparing the TRUS-defined intraoperative prostate volume
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to the post-implant imaging prostate volume. Acher et al.42 found mean differences of
D90 was 13 Gy using intraoperative TRUS volume to post-operative CT volume, and 17 Gy
using intraoperative TRUS volume to post-operative CT-MRI volume.42 Ash et al.30 found
a significant correlation between D90 and the ratio of CT and TRUS volumes. However,
they found that although D90 and PSA control was significant in the low-risk group, it
was not significant in the intermediate- and high-risk groups, potentially due to presence of
edema distorting the dose-volumes, underdosing occurring in non-diseased areas, or failure
occurring outside the prostate. Crook et al.41 found statistically significant residual edema
in 12 % (29 patients) of their study cohort whereby the mean prostate volume was 34.8 cc
before the implant but 46.1 cc a month after the implant.
Physician contouring The previous contouring experience, training, bias, stress and
fatigue experienced by the physician may affect the subjective delineation of the prostate.
Crook et al.43 found that the contouring of the prostate volumes on CT images by inex-
perienced physicians were significantly smaller than the corresponding volumes on MRI
images due to underestimation of prostate edema and overcorrection attempts to exclude
the anterior venous plexus and puborectalis muscle. Uncertainties in volume propagate into
uncertainties in DVH parameters. Crook et al.43 found that prostate contouring on CT
and MRI images resulted in V100 difference of 2.4 % by an experienced physician versus
9.4 % and 4.4 % by 2 inexperienced physicians. Dubois et al.44 found that whether prostate
volumes contoured on CT and MRI images were significantly different is dependent on the
individual observers.
Dose calculation formalism The dose calculation assumes all tissue density to be water-
equivalent, according to the American Association of Physicists in Medicine Task Group 43
(AAPM TG-43) report.45 Since the dose is delivered at short ranges to tissues with similar
electron densities, no electron density corrections are used.15
Treatment planning system Dose calculation in the TPS introduces uncertainties in
implant quality evaluation. Different TPS may adopt different dose calculation input data
from literature, especially for newer radioisotopes released after the publication of AAPM
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reports concerning brachytherapy dosimetry.15,45–48 Different TPS may also calculate volume
based on the user-provided contours differently∗∗.
Post-implant imaging modality The choice of imaging modality for post-implant
dosimetry is a significant contributor to uncertainties in implant quality evaluation and
is the central motivation of this dissertation. The post-implant imaging modality affects
the precision of the seed localization,49 precision27,31,44,50–52 and accuracy51,53–55 of prostate
delineation, as well as the precision and accuracy of normal tissue contours.55,56
1.6 Post-implant Dosimetry Imaging Modalities
DVH parameters generated from post-implant dosimetric assessment are widely used as
metrics to estimate the implant quality. To estimate the extent of the radiation exposure
in both the cancerous and normal cells, two main pieces of information are needed from
the post-implant images: (1) the radioactive seeds’ precise locations; (2) the boundaries of
the prostate and normal structures adjacent to the prostate, such as the bladder, urethra,
rectum and penile bulb.
The accuracy of localizing the radioactive seeds and contouring the anatomical volumes
depends on the post-implant image quality. Therefore, post-implant imaging is crucial for
ensuring the quality of the implant. The two main imaging modalities used for post-implant
imaging are CT and MRI.
1.6.1 Computed Tomography
The current standard of care is to perform a CT scan after implantation to delineate the
anatomy, identify the radioactive seeds, and verify the radiation dose distribution.10,58
Contrast on CT images are mainly defined by the object contrast, namely the imaged
object’s effective atomic number.
The advantage of CT for the purposes of post-implant dosimetry is that the radioactive
seeds can be easily visualized on a CT scan (Figure 1.7a). The seeds’ high atomic number
∗∗See Chapter 2 for a comparison of calculations of dose, volume and dose-volume histogram parameters
by two different TPS
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(a) CT (b) MRI
Figure 1.7: Comparison of CT and MRI postimplant images. Brachytherapy seeds can be
more definitively identified using CT, but appear as signal voids with MRI. However, the
anatomical details of the male pelvis are clearly more visible with MRI. Reprinted from
T. Y. Lim, R. J. Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao,
K. S. Martirosyan, and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl
cysteine (C4) contrast agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10
(2014), pp. 2505–1657 ( c©Institute of Physics and Engineering in Medicine. Reproduced by
permission of IOP Publishing. All rights reserved).
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and density result in high contrast between the seeds and prostatic tissue.
The disadvantage of CT for the purposes of post-implant dosimetry is that poor soft
tissue contrast inherent to CT makes it difficult to visualize the prostatic capsule,27,51,52
and other tissue may be mistaken for the prostate.59 Also, metallic artifacts introduced
by the seeds due to the high atomic number of the seed’s titanium casing potentially
obscures visualization of the prostate boundaries and also confounds definitive seed centroid
localization.27
CT-only post-implant dosimetry is common at most institutions, even with uncertainties
in the contouring of the prostate and critical soft tissue nearby††.
1.6.2 Magnetic Resonance Imaging
Another post-implant imaging modality is MRI, whereby the hydrogen protons precessing
at varying frequencies provide contrast and spatial information†. Currently, MRI is the
optimum imaging modality for staging of a suspected primary prostate malignancy.60–62
Beyersdoff et al.60 reported 75% accuracy of prostate cancer staging with MRI.
The advantage of MRI for the purposes of post-implant dosimetry is superior soft-tissue
visualization of the prostate and surrounding critical structures.61,63–65 A variety of MRI
imaging techniques allows for detailed visualization of pelvic anatomy.64,66 Improved visual-
ization can be seen on MRI images compared to CT images for intraprostatic zonal detail,63
extraprostatic extension,63 prostate apex and base,20 internal pudendal artery,5,20 neurovas-
cular bundles,55,63,67,68 penile bulb,20,55,68 rectal wall,20,55,67 bladder neck,20 urethra55 and
urinary sphincters.5,51,54,56 Anatomical visualization of critical structures is important to
potentially correlate the dose delivered to these structures to the treatment complications,20
such as those described in Section 1.4.
The disadvantage of MRI for post-implant dosimetry is that the metallic radioactive seeds
and spacers appear as negative voids on MRI images (Figure 1.7b), thus confounding precise
detection of seed positions.27,49,69–71 The seeds may be mistaken for needle tracks72 or blood
vessels,69,70 or obscured by other inhomogeneities such as hemorrhage, calcifications, or air
††See Section 5.1.1 for further discussion of the advantages and disadvantages of CT-only post-implant
dosimetry.
†See Section 3.1.1 for more details about the contrast mechanism on MRI images.
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bubbles.73 Definitive seed localization remains the main challenge, preventing widespread
use of MRI as a single-imaging modality for post-implant dosimetry.20,74
Due to the excellent soft tissue contrast on MRI images and high seed visibility on
CT images, CT-MRI fusion-based post-implant dosimetry is the post-implant dosimetry
approach recommended by the American Brachytherapy Society10 and regarded as the gold-
standard for prostate edge identification.43 However, CT-MRI fusion-based post-implant
dosimetry requires acquisition of two sets of images, thereby introducing further uncertainties
from the fusion process as well as logistical issues‡. MRI-only post-implant dosimetry is not
done as part of the routine clinical workflow of any institutions, but there are many ongoing
investigations into the possibility of MRI-only post-implant dosimetry§
1.7 Encapsulated Contrast Agent Markers (Sirius MRI Mark-
ers)
To enable MRI-only post-implant assessment, encapsulated contrast agent markers have
been proposed as a potential solution.20 The encapsulated contrast agent markers, also
known as Sirius MRI markers, contain cobalt dichloride N-acetyl cysteine (CoCl2-NAC;
C4 contrast agent) encapsulated in a polyetheretherketone (PEEK) casing. These Sirius
MRI markers are hyperintense on MRI images and are designed to be placed adjacent to
hypointense seeds.
Frank et al.20 first identified the CoCl2-glycine contrast agent to have the greatest signal
when compared to various contrast agents, namely Omniscan (Gadodiamide), L-PG-Bz-
DTPA-Gd, Feridex IV, colloidal nanoparticle solutions of Fe3O4, CoFe2O4, Mn-Zn and Ni-Zn
ferrites (Figure 1.8). Frank et al.20 also first visualized the C4 contrast agent encapsulated
in marker stranded with nonradioactive seeds implanted into a canine prostate (Figure 1.9).
Furthermore, the Sirius MRI markers do not alter the radiation dose distribution.75,76
Frank et al.75 reported that the Sirius MRI markers adjacent to the radioactive seed did not
‡See Section 5.1.2 for further discussion of the advantages and disadvantages of CT-MRI fusion-based
post-implant dosimetry.
§See Section 5.1.3 for further discussion of the advantages and disadvantages of MRI-only post-implant
dosimetry.
21
Chapter 1 Introduction
Figure 1.8: Novel C4 agent with positive contrast in 1.5 T magnetic resonance imaging T1-
weighted sequence. (a) Coronal and (b) sagittal images. I indicates manufactured titanium
seeds with paramagnetic and supraparamagnetic contrast agents. ”Blooming” susceptibility
artifact of titanium seeds shown. II indicates various paramagnetic and supraparamagnetic
contrast agents in plastic vials, with C4 agent showing positive magnetic resonance imaging
contrast. Reprinted from S. J. Frank, R. J. Stafford, J. A. Bankson, C. Li, D. A. Swanson,
R. J. Kudchadker, and K. S. Martirosyan. “A novel MRI marker for prostate brachytherapy”.
In: Int J Radiat Oncol Biol Phys 71.1 (2008), pp. 5–820 (license number: 3876101018346).
Figure 1.9: Imaging of standard titanium seeds with embedded encapsulated contrast agent
marker in canine prostate incorporated into phantom. (a) Canine prostate embedded in
agarose gel phantom and strand of standard titanium seeds and encapsulated contrast agent
marker with C4 agent between seeds. (b) Sagittal, 1.5 T T1-weighted magnetic resonance
image of canine prsotate with strand of standard titanium seeds containing encapsulated
contrast agent marker with C4 agent, permitting accurate identification of seeds. Reprinted
from S. J. Frank, R. J. Stafford, J. A. Bankson, C. Li, D. A. Swanson, R. J. Kudchadker,
and K. S. Martirosyan. “A novel MRI marker for prostate brachytherapy”. In: Int J Radiat
Oncol Biol Phys 71.1 (2008), pp. 5–820 (license number: 3876101018346).
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significantly affect the seed’s 2D anisotropy function F (r, θ) or 1D anisotropy function φ(r)
as measured by thermoluminescent dosimeters in a water phantom¶. Frank et al.75 also
verified that the Sirius MRI markers can still be visualized by MRI after being irradiated
with a dose equivalent to the cumulative dose in a month for a typical prostate implant.
The Monte Carlo evaluation of the dosimetric influence of Sirius MRI markers (Figure 1.10)
by Melhus et al.76 found no significant impact on DVH parameters due to the 1% cobalt
chloride concentration marker (chelated with glycine) placed next to I-125, Pd-103 and
Cs-131 seeds.
N-acetyl-cysteine (NAC, C5H9NO3S) was later used as the chelate instead of glycine
(C2H5NO2), as NAC increased urinary and fecal cobalt excretion and lowered liver and spleen
cobalt levels.77 To evaluate the effect of potential leakage of the Sirius MRI markers, Frank
et al.77 evaluated the biodistribution and toxicity of CoCl2-NAC by directly injecting the
contrast agent into rats, and found no systemic toxicity with dual renal-hepatic elimination
at the dose and volume consistent with a volumetric prostate implant.
Nevertheless, use of the Sirius MRI markers is associated with some limitations. A caveat
of using Sirius MRI markers is the indirect correspondence between hyperintense signals
on MRI images and seed positions. Since the Sirius MRI markers are placed next to the
seeds, contrary to conventional CT images, the bright signals do not represent the seeds
themselves, but represent the markers instead.
Another limitation from the use of Sirius MRI markers is the restriction to stranded (not
loose) seeds. Since the markers need to be placed at a fixed distance adjacent to the seeds,
the markers and seeds must be stranded together. Furthermore, migrated seeds would be
difficult to localize. Marker-based seed localization depends on the proximity of a Sirius
MRI marker to definitively localize a seed. A migrated seed then would be difficult to
localize. However, compared to loose seeds, stranded seeds rarely migrate.33,34 Moreover,
from our institution’s experience,78 lower overall activity is required for treatment using
stranded seeds instead of loose seeds, resulting in greater implant efficiency and improved
dose homogeneity.
¶See Section 2.1.2 for the description of these anisotropy functions and the TG-43 dose calculation
formalism.
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Figure 1.10: The relative dose distributions for Pd-103 (upper panels, with 3% bin width)
and I-125 (lower panels, with 2% bin width) for a source in homogeneous water and a source
with adjacent spacer for the model 6711 I-125 source and three different spacers. In the lower
left corner of each panel, the bold horizontal striped object represents the upper half of the
source, and the vertically striped object represents the spacer. Reprinted from C. S. Melhus,
J. K. Mikell, S. J. Frank, F. Mourtada, and M. J. Rivard. “Dosimetric influence of seed
spacers and end-weld thickness for permanent prostate brachytherapy”. In: Brachytherapy
(2013)76 (license number: 3876101458418).
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Apart from limitations intrinsic to the design of the Sirius MRI markers, other limitations
for the practical adoption of Sirius MRI markers in the clinical setting are addressed in
this dissertation, namely a TPS allowing for MRI-based brachytherapy, Sirius MRI marker
relaxation characterization, a pulse sequence to visualize the Sirius MRI markers, and manual
seed localization.
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2.1 Background
2.1.1 Radioactive Seeds
For permanent prostate implants, radioactive seeds with low dose rate (< 2 Gy/h) are used.9
To perform dose calculations, clinical brachytherapy treatment planning systems store various
constants associated with these seeds for various types of radionuclides and manufacturers.
The dose calculation constants and dose calculation formalism will be described in the next
section.
Commonly used radionuclides are Iodine-125, Pd-103 and Cs-131 (Table 2.1). Due to
differences in half-life and dose rate, the radionuclide chosen dictates the treatment dose
prescribed to the planning target volume (PTV).10 For I-125 monotherapy, the prescription
dose to the PTV ranges between 140 Gy to 160 Gy, while for Pd-103 monotherapy, the
prescription dose to the PTV ranges between 110 Gy to 125 Gy.10
Table 2.1: Model numbers and characteristics of radioactive sources. Reprinted from S. K.
Dhanesar, T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank, and R. J. Kudchadker. “Evaluation
of the MIM Symphony treatment planning system for low-dose-rate prostate brachytherapy”.
In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579 (licensed under a Creative Commons
Attribution 3.0 License).
I-125 I-125 Pd-103 Cs-131
Model number IAI-125A 6711 200 Cs-1
Dose rate constant Λ (cGy/h/U) 0.981 0.965 0.686 1.059
Half-life (days) 59.399 59.399 16.991 9.689
Length (cm) 0.45 0.456 0.45 0.45
The construction of the seed depends on the seed manufacturer, resulting in differences
in capsule thickness, weld thickness, weld material, radioactivity carrier material, radio-
opaque material shapes, and other seed variations (Figure 2.1).15 Al-Qaisieh et al.29 found
statistically significant differences in prostate D90 from five different manufacturers’ I-125
seeds placed at the same locations. They also found that although visibility on CT images
were similar, one of the source types (IBT Intersource 1251L) has a significantly larger
susceptibility artifact on MRI images that could impede contouring.29
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(a) I-125 (model 6711)
(b) Pd-103 (model 200)
(c) Cs-131 (model Cs-1)
Figure 2.1: Different seed manufacturers have different seed geometries and internal con-
struction. (a) I-125 and (b) Pd-103 seed schematic diagrams adapted from Mark J. Rivard,
Bert M. Coursey, Larry A. DeWerd, William F. Hanson, M. Saiful Huq, Geoffrey S. Ibbott,
Michael G. Mitch, Ravinder Nath, and Jeffrey F. Williamson. “Update of AAPM Task
Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations”. In:
Medical Physics 31.3 (2004), pp. 633–67415 (with permission from the American Association
of Physicists in Medicine). (c) Cs-131 seed schematic diagram adapted from R. Tailor,
G. Ibbott, S. Lampe, W. B. Warren, and N. Tolani. “Dosimetric characterization of a
Cs131Cs131 brachytherapy source by thermoluminescence dosimetry in liquid water”. In:
35.12 (2008), pp. 5861–880 (with permission from the American Association of Physicists in
Medicine.)
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Figure 2.2: The isodose curves produced by I-125 and Pd-103 sources with air kerma strength
of 100 U. The dose rates for the isodose curves starting from the outside were 2, 5, 10, 20,
50, 100 and 200 cGy/h. Adapted from Ravinder Nath, Lowell L Anderson, Gary Luxton,
Keith A Weaver, Jeffrey F Williamson, and Ali S Meigooni. “Dosimetry of interstitial
brachytherapy sources: Recommendations”. In: Medical physics 22.2 (1995), pp. 209–23445
(with permission from the American Association of Physicists in Medicine).
2.1.2 Dose Calculation for Prostate Implants
Brachytherapy treatment planning systems calculate dose using the formalism recommended
by AAPM TG-43.45 Prior to the AAPM TG-43 report,45 calculation of 2D dose distribution
can be accomplished for a point isotropic source, but not for actual brachytherapy seeds with
considerable anisotropy (Figure 2.2). To overcome this problem, the AAPM TG-43 formalism
used measurements of dose distributions generated by actual brachytherapy seeds.45
Using the 2D dose calculation formalism, the dose rate D˙(r, θ) for a brachytherapy seed
at a point (r, θ) in water is
D˙(r, θ) = Sk · Λ · G(r, θ)
G(r0, θ0)
· g(r) · F (r, θ) (2.1)
where Sk is the air kerma strength, Λ is the dose rate constant, G(r, θ) is the geometry
function, G(r0, θ0) is the geometry function at the reference point, g(r) is the radial dose
function, and F (r, θ) is the 2D anisotropy function.45 From Figure 2.3, r denotes the distance
from the center of the active source to the point of interest, r0 denotes the reference distance
of 1 cm, θ denotes the polar angle specifying the point of interest relative to the source
longitudinal axis, and the reference polar angle θ0 defines the source transverse plane which
is specified to be 90◦ or pi/2 radians.45
The air kerma strength Sk of a brachytherapy seed characterizes the dose delivered to
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Figure 2.3: Coordinate system used for brachytherapy dosimetry calculations. Reprinted
from Mark J. Rivard, Bert M. Coursey, Larry A. DeWerd, William F. Hanson, M. Saiful Huq,
Geoffrey S. Ibbott, Michael G. Mitch, Ravinder Nath, and Jeffrey F. Williamson. “Update
of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose
calculations”. In: Medical Physics 31.3 (2004), pp. 633–67415 (with permission from the
American Association of Physicists in Medicine).
air along the transverse plane (Unit: U, where 1 U = 1 cGycm2/h).45
The dose rate constant Λ defines the dose rate to water at r = 1 cm along the seed’s
perpendicular bisector from a 1 U seed (Unit: cGy/h/U).45 Λ includes the effect of seed
geometry, spatial distribution of radiation in the seed, encapsulation, self-filtration, and
scattering in water.45
The geometry function G(r, θ) accounts for dose variation due to the spatial distribution
of activity in the seed. For the line source approximation, where L is the active length of
the source, the geometry function is
GL(r, θ) =

β/(Lr sin θ) if θ 6= 0◦
(r2 − L2/4)−1 if θ = 0◦
(2.2)
At larger distances (r >> L), the radiation dose from a brachytherapy seed can be approxi-
mated as a point source and the geometry function can be written as
GP (r) = r
−2 (2.3)
In the equation for dose rate calculation (Equation 2.1), the geometry function G(r, θ) is
normalized to a reference point at r = 1 cm along a perpendicular bisector (Figure 2.3).
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The radial dose function g(r) characterizes the dose rate fall-off along the seed’s transverse
axis due to scatter and absorption in the medium (Unit: dimensionless).
The 2D anisotropy function F (r, θ) characterizes the angular dose rate variation around
the source due to self-absorption, attenuation by the capsule, and other unaccounted
dosimetric factors (Unit: dimensionless).
The values for the radial dose function g(r) and the 2D anisotropy function F (r, θ) are
source-specific, and can be obtained from AAPM reports45 for certain source models∗ or
from the manufacturer directly.
Finally, using Equation 2.1 and the half-life (T1/2) for an isotope, the dose D(r, θ) at a
point (r, θ) can be calculated as
D(r, θ) = ln 2 · T1/2 · D˙(r, θ) (2.4)
The 2D dose calculation formalism can be applied to brachytherapy seeds with known L
and orientations. To simplify seed localization procedures15 or if too many implanted seeds
are randomly oriented,45 the 1D dose calculation formalism15 can be used to calculate dose
rate
D˙(r) = Sk · Λ · GL(r, θ0)
GL(r0, θ0)
· gL(r) · φan(r) (2.5)
where, the subscript L is for line source approximation, P for point source approximation,
and φan(r) is the 1D anisotropy function.
45 The 1D anisotropy function φan(r) defines the
ratio of dose rate at r averaged by the solid angle, to the dose rate at r on the transverse
plane.45
Although Equation 2.5 is the recommended15 implementation for 1D dose calculation
formalism, most TPS use
D˙(r) = Sk · Λ · (r0/r)2 · gP (r) · φan(r) (2.6)
∗The values reported were consensus values from several sources obtained by measurements, verified by
Monte Carlo simulations, and can be found in figures and tables relevant to the source-of-interest.
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Figure 2.4: Treatment planning in the VariSeed brachytherapy TPS with TRUS images.
2.1.3 Treatment Planning Systems
VariSeed 8.0 was the prostate implant brachytherapy TPS previously used at our institution
(Figure 2.4). VariSeed is commonly used for TRUS- and CT-based treatment planning.
Recently, interest in MRI-based treatment planning has considerably increased owing to
the ability of MRI to provide superior delineation of soft tissue. Particularly, the American
Brachytherapy Society recommended fusion of CT and MRI images as useful (but not
mandatory) for post-implant dosimetry.10 At the time of investigation, the VariSeed TPS
has limited flexibility in incorporating MRI images.
The MIM Symphony LDR prostate brachytherapy TPS has recently been introduced
into the market (Figure 2.5). MIM Symphony provides better tools for TRUS-MRI fusion,
CT-MRI fusion, and MRI-only treatment planning. MIM Symphony has several advantages
compared to VariSeed: multimodality treatment planning available based on CT, TRUS
and MRI (Figure 2.6), compared to CT and TRUS capabilities only in VariSeed; enhanced
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Figure 2.5: Treatment planning in the MIM Symphony brachytherapy TPS with TRUS
images.
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Figure 2.6: MIM Symphony allows treatment planning based on MRI images, apart from
CT and TRUS images. The top row shows imported MRI images, while the bottom row
shows the contours and planned seed locations.
MRI, CT and US fusion capability; algorithm for auto-contouring of anatomical structures;
plan library available for faster treatment planning; improved intraop dosimetry with needle
shifts and deflections; dose summation with other plans (external beam and brachytherapy);
plans from multiple TPS can be imported (VariSeed requires a VariSeed-specific format);
Matlab and Java codes can be run as extensions within the MIM Symphony TPS.
The disadvantage of MIM Symphony compared to VariSeed is that it is a relatively new
TPS in the market so it is not as widely used in clinics nationwide. Therefore, available
information related to the dosimetric and treatment planning validation of this TPS was
limited. The only other available study that compared VariSeed TPS with MIM Symphony
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was by Gossman et al.81 who evaluated DVH parameters for I-125 (Model 6711). In this
chapter, I describe further comparisons of the dosimetric accuracy of MIM Symphony TPS
to VariSeed TPS.
2.2 Purpose
The ultimate goal of Sirius MRI markers is to enable MRI-only post-implant dosimetry for
better evaluation of dose-response relationships. The VariSeed TPS previously used at our
institution for LDR prostate brachytherapy treatment planning did not allow for an MRI-only
LDR prostate brachytherapy workflow. Conversely, the MIM Symphony TPS, which has
better tools for incorporating MRI into the workflow was a new TPS with few documentation
in literature. These two TPS may integrate different volume or dose calculation formalisms.
Therefore, in this chapter, I evaluate the volume and dose calculations of these two TPS,
as well as the subsequent dose-volume histogram parameters generated that may impact
evaluation of implant quality.
2.3 Methods
2.3.1 Evaluation using VariSeed Test Procedures
As a preliminary evaluation of the MIM Symphony TPS, I compared the MIM Symphony
TPS to the VariSeed TPS using the VariSeed Test Procedures82 and Test Data for I-125
(Model 6711).83 Briefly, the tests verify dose calculations (within- and through-plane), display
of isodose levels, and dose volume calculations.
2.3.2 Evaluation on Phantom Images
A QA phantom (CIRS Brachytherapy QA Phantom Model 045 SN#D7210-3) which has
three ellipsoid objects with certified volumes was imaged using CT and MRI. The images
were imported into MIM Symphony and VariSeed and then contoured independently. The
auto-contouring tools of MIM Symphony TPS were used.
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2.3.3 Evaluation on Patient Images
VariSeed TPS was previously used at our institution for LDR prostate brachytherapy
treatment planning. As part of our institution’s clinical workflow, three treatment plans
are generated for each patient during the course of the treatment. The pre-implant plan
is generated prior to treatment and is based on ultrasound images; this plan is used to
determine the number of seeds, needles, and loading patterns needed for treatment. For the
pre-implant plan, sonographic images of the prostate are acquired at 5 mm intervals using
the Sonoline G20 ultrasound unit (Siemens Medical Solutions, Mountain View, CA), and
the images are then transferred to the VariSeed TPS. The radiation oncologist contours
the prostate, bladder, rectum, urethra, and seminal vesicles. A PTV of 3 mm around the
prostate volume is generated, except at the posterior aspect of the prostate along the
rectum, where no margin is added. To determine the quality of the implantation, a CT
scan is performed immediately following the implantation and used to generate the Day 0
post-implant plan. After the prostate edema has resolved in approximately a month, another
CT scan is performed to generate the Day 30 post-implant plan.
To compare the dosimetric calculation of the VariSeed TPS and MIM Symphony TPS,
I evaluated 100 plans in each of the two TPS. I evaluated 25 pre-implant plans and 25
post-implant (Day 30) patient plans for two commonly used seed models at our institution,
namely I-125 (Oncoseed Model 6711, GE Healthcare, Arlington Heights, IL) and Pd-103
(Theraseed Model 200, Theragenics Corporation, Buford, GA). The seed characteristics were
provided in Table 2.1. In this study, I compared the volumes and DVH parameters of the
prostate, bladder, and rectum. For the prostate, the DVH parameters examined were D90,
V100, V150 and V200. For the bladder, the DVH parameters examined were V50, V100, and
V150. Similarly, for the rectum, the DVH parameters examined were V50, V100, and V150.
Considering that VariSeed was our institution’s routine clinical TPS, the DVH and
volume values for this TPS were directly reported from clinical plans. For the MIM
Symphony TPS, the seed locations and contours were exported from the VariSeed TPS
to the MIM Symphony TPS. From these 2D contours and seed coordinates, the volume
and dose were calculated. The line model was specified for dose calculations in both TPS.
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Figure 2.7: The dose volume histogram (DVH) displayed in the MIM Symphony treatment
planning system. A fixed annotation was made on the prostate DVH (blue line) for D90
(the minimum dose covering 90% of the prostate volume). With the rectum selected as
the structure of interest, moving the cursor shifts the white lines connecting the rectum
DVH (green line) to the axes and updates the accompanying annotation, thus allowing for
interrogation of the relation between any desired dose or volume.
In VariSeed, the dose resolution was specified to be 1 mm× 1 mm× 5 mm for pre-implant
plans, and 1 mm× 1 mm× 2.5 mm for post-implant plans. In MIM, the dose resolution was
specified to be 1 mm× 1 mm× 5 mm for pre-implant plans, and 1 mm× 1 mm× 1.67 mm
for post-implant plans. In the VariSeed TPS, the DVH parameter and volume values were
obtained from the the plan alerts or interpolated from the DVH tables (Figure 1.6). In the
MIM Symphony TPS, the DVH parameter and volume values were obtained directly from
annotations made on the DVH itself (Figure 2.7).
Both TPS had the same information for calculation of dose and volume since the
defined anatomical contours and seed locations were transferred from VariSeed to MIM. Any
differences in the calculated DVH parameters then arise from differences in dose and volume
calculation performed by the two TPS. For each DVH parameter evaluated, the difference
was calculated between the values from MIM Symphony and VariSeed. A positive difference
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indicated that MIM Symphony calculated a greater value than VariSeed, and a negative
difference indicated that VariSeed calculated a greater value than MIM Symphony.
2.4 Results and Discussion
2.4.1 Evaluation using VariSeed Quality Assurance User Test Procedures
The VariSeed quality assurance user test procedures were used during the preliminary phase
of evaluating the MIM Symphony TPS. Using the VariSeed quality assurance user test
procedures, the dose calculated by VariSeed and MIM Symphony were not significantly
different (Figures 2.8, 2.9, 2.10 and 2.11).
Using finer distance increments, Dhanesar et al.79 tabulated the percentage dose dif-
ferences between MIM Symphony TPS, VariSeed TPS and TG-43 calculations for Cs-131
(Proxcelan Model Cs-1, IsoRay Medical Inc., Richmond, WA), Pd-103 (Theraseed Model 200,
Theragenics Corporation, Buford, GA), and two models of I-125 sources (Oncoseed Model
6711, GE Healthcare, Arlington Heights, IL; and Advantage Model IAI-125A, Isoaid, LLC,
Port Richey, FL). Using the 2D dose calculation formalism, dose calculations by the MIM
Symphony TPS, VariSeed TPS and the TG-43 formalism agreed within 0.5% for r > 1 cm.79
Using the 1D dose calculation formalism, the dose calculations by the MIM Symphony TPS
was within 1.4% to dose calculations using the TG-43 formalism, and within 1% compared
to dose calculations by the VariSeed TPS, for r > 1 cm.79
2.4.2 Evaluation on Phantom Images
The evaluation on phantom images was of the volume calculations performed by MIM
Symphony versus VariSeed. The structures were contoured using the auto-contouring tool on
MIM Symphony and manually contoured on VariSeed. Comparisons using phantom images
yielded less than 1 % difference between the volume calculated by MIM Symphony and the
actual volume of the phantom. Comparisons were also made to the volumes calculated by
VariSeed. Table 2.2 summarizes the results for different structures.
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(a) Point model (b) Line model
Figure 2.8: Comparison of dose point calculation test results. VariSeed values obtained from
User Test Data tables. Distances were specified in the y-direction.
(a) VariSeed (b) MIM Symphony
Figure 2.9: Comparison of isodose level display functions. The isodose lines should intersect
each crosshair of the same row as the source.
Table 2.2: Volume calculations of known structures by MIM Symphony and VariSeed.
Reprinted from S. K. Dhanesar, T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank, and
R. J. Kudchadker. “Evaluation of the MIM Symphony treatment planning system for
low-dose-rate prostate brachytherapy”. In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579
(licensed under a Creative Commons Attribution 3.0 License).
Volumes (cm3) Volume Difference (%)
Actual MIM Symphony VariSeed MIM Symphony vs.
Actual
VariSeed vs.
Actual
Small 3.45 3.43 3.47 -0.6 0.6
Medium 8.51 8.57 8.45 0.7 -0.7
Large 19.78 19.89 20.06 0.6 1.4
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Figure 2.10: Comparison of dose volume test results. Activity was calculated using the
anisotropy factor for a point source.
Figure 2.11: Comparison of dose calculations in z-direction.
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Figure 2.12: Differences between the volumes calculated in MIM Symphony and those
calculated in VariSeed for the prostate, bladder, and rectum. Dose volume histogram data
for iodine-125 (I-125; Model 6711) and palladium-103 (Pd-103; Model 200) are shown. The
bottom and top of each box are the first and third quartiles, the line inside the box indicates
the median, and the ends of the whiskers indicate the minimum and maximum values. Total
volumes are shown as mean ± standard deviation. Reprinted from S. K. Dhanesar, T. Y.
Lim, W. Du, T. L. Bruno, S. J. Frank, and R. J. Kudchadker. “Evaluation of the MIM
Symphony treatment planning system for low-dose-rate prostate brachytherapy”. In: J Appl
Clin Med Phys 16.5 (2015), pp. 62–7579 (licensed under a Creative Commons Attribution
3.0 License).
2.4.3 Evaluation on Patient Images
The evaluation on phantom images were of the volume and dose-volume histogram parameter
calculations performed by MIM Symphony versus VariSeed.
2.4.3.1 Comparison of Volume Calculations
The volume calculations for the prostate and rectum did not differ substantially (Figure
2.12). The bladder showed higher volume differences between MIM Symphony and VariSeed
than the other two structures in the pre-implant plans (Figure 2.12). These differences
may be due to the large Z direction resolution (5 mm used in both MIM Symphony and
VariSeed), large contoured areas, partial contouring (bladder contours on a few slices only)
and interpolation of VariSeed data.
The greater volume differences calculated on pre-implant plans compared with post-
implant plans are attributable to resolution differences between the pre-implant ultrasound
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images and the finer-resolution post-implant CT images. On the other hand, as noted above,
the Z resolution for the post-implant plans in MIM Symphony was 1.67 mm compared with
2.5 mm in VariSeed. This resolution discrepancy may have caused differences in post-implant
comparisons between the two systems.
To further investigate the volume calculations of the two TPS, volumes generated from
rectangular contours drawn on 2 slices (Case A), 4 slices (Case B), 6 slices (Case C) and 8
slices (Case D) were calculated. Volumes calculated on VariSeed were based on the volumes
defined from the topmost contour to the bottommost contour. On the other hand, volume
calculated on MIM were based on volumes defined with half-slice extrapolations from the
topmost and bottommost contours (Figure 2.13).
This finding is consistent with a previous study by Gossman et al..81 They contoured
0.5 cm × 5 cm over 3 slices (2.5 mm slice thickness) and found the resulting volume was
1.875 cm3 in MIM Symphony.
Determination of the more accurate TPS’ volume calculation method is dependent on the
contoured structure. For instance, for rounded structures such as the prostate, the half-slice
extrapolations round-up the base and apex of the prostate, thus giving a more accurate
representation of true anatomy. However, if the physician is unaware of these extrapolations
intrinsically performed by the MIM Symphony TPS, overcontouring may ensue. In that
case, the what-you-contour-is-what-you-get approach of the VariSeed TPS may lead to more
accurate structure definition.
This observed difference in volume calculation methods may have accounted for the
greater volume differences found in pre-implant plans compared to post-implant plans. For
instance, due to the bladder not fully encompassed in the imaging FOV, contouring of the
bladder was partial, resulting in a large area on the topmost slice of the bladder contour.
Since the pre-implant TRUS images were acquired at lower slice resolution compared to the
post-implant CT images, the effect of half-slice extrapolations performed by MIM Symphony
was enhanced, and greater calculated volume differences were observed (Figure 2.12).
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Figure 2.13: Comparison of volume calculation methods in VariSeed and MIM Symphony
using rectangular contours drawn on 2, 4, 6 and 8 slices for the volume calculation.
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Figure 2.14: Differences between the prostate V100, V150, and V200 calculations in MIM
Symphony and those in VariSeed. Vx = portion of the total prostate volume receiving x%
of the prescribed dose. Dose volume histogram data for iodine-125 (I-125; Model 6711)
and palladium-103 (Pd-103; Model 200) are shown. The bottom and top of each box are
the first and third quartiles, the line inside the box indicates the median, and the ends of
the whiskers indicate the minimum and maximum values. Reprinted from S. K. Dhanesar,
T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank, and R. J. Kudchadker. “Evaluation of
the MIM Symphony treatment planning system for low-dose-rate prostate brachytherapy”.
In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579 (licensed under a Creative Commons
Attribution 3.0 License).
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Table 2.3: Differences between the prostate D90 calculations in MIM Symphony and those
in VariSeed. Reprinted from S. K. Dhanesar, T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank,
and R. J. Kudchadker. “Evaluation of the MIM Symphony treatment planning system for
low-dose-rate prostate brachytherapy”. In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579
(licensed under a Creative Commons Attribution 3.0 License).
Differences in prostate D90 (Gy)
Pre-implant Post-implant
I-125 Pd-103 I-125 Pd-103
Mean 0.73 0.18 1.46 1.99
Standard deviation 0.64 0.68 1.40 1.29
Minimum -1.35 -2.52 -0.32 -0.23
Maximum 2.70 0.85 6.80 5.75
2.4.3.2 Comparison of DVH Parameter Calculations
Prostate DVH Parameters The differences between the prostate V100, V150, and V200
values calculated in MIM Symphony and those calculated in VariSeed is shown in Figure
2.14. Because the prostate V100, V150, and V200 values were recorded as percentages of
the total prostate volume, the differences in these values are reported in percentages as well.
Mean differences in prostate V100, V150, and V200 values were within 2 % (Figure 2.14).
Table 2.3 shows the mean, standard deviation, and minimum and maximum differences in
prostate D90 values.
Bladder DVH Parameters The differences in the V50, V100, and V150 values calculated
by the two TPS for the bladder did not differ substantially (Figures 2.15). Mean differences
in bladder V50, V100, and V150 values were within 2 cc (Figure 2.15). The differences
in bladder V50 values were slightly higher. This may be due to the differences in volume
calculations as described in Section 2.4.3.1.
Rectum DVH Parameters The differences in the V50, V100, and V150 values calculated
by the two TPS for the rectum did not differ substantially (Figure 2.16). Mean differences
in rectum V50, V100 and V150 values were within 0.5 cc (Figure 2.16).
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Figure 2.15: Differences between the bladder V50, V100, and V150 calculations in MIM
Symphony and those in VariSeed. Vx = portion of the bladder volume receiving x% of
the prescribed dose. Dose volume histogram data for iodine-125 (I-125; Model 6711) and
palladium-103 (Pd-103; Model 200) are shown. The bottom and top of each box are the
first and third quartiles, the line inside the box indicates the median, and the ends of the
whiskers indicate the minimum and maximum values. Reprinted from S. K. Dhanesar,
T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank, and R. J. Kudchadker. “Evaluation of
the MIM Symphony treatment planning system for low-dose-rate prostate brachytherapy”.
In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579 (licensed under a Creative Commons
Attribution 3.0 License).
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Figure 2.16: Differences between the rectum V50, V100, and V150 calculations in MIM
Symphony and those in VariSeed. Vx = portion of the rectal volume receiving x% of
the prescribed dose. Dose volume histogram data for iodine-125 (I-125; Model 6711) and
palladium-103 (Pd-103; Model 200) are shown. The bottom and top of each box are the
first and third quartiles, the line inside the box indicates the median, and the ends of the
whiskers indicate the minimum and maximum values. Reprinted from S. K. Dhanesar,
T. Y. Lim, W. Du, T. L. Bruno, S. J. Frank, and R. J. Kudchadker. “Evaluation of
the MIM Symphony treatment planning system for low-dose-rate prostate brachytherapy”.
In: J Appl Clin Med Phys 16.5 (2015), pp. 62–7579 (licensed under a Creative Commons
Attribution 3.0 License).
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2.5 Conclusion
2.5.1 Summary
This chapter described the comparison of two LDR prostate brachytherapy TPS, namely
Varian VariSeed 8.0 and MIM Symphony 5.4. Overall, the differences in the DVH parameters
evaluated in this work do not disqualify MIM Symphony from clinical treatment planning.
2.5.2 Limitations
A limitation of this study was that the Z resolution for dose calculations for post-implant
plans is different for VariSeed and MIM. Both VariSeed and MIM Symphony only allowed
specific numeric settings for the dose resolution in Z, namely 0.5 mm, 0.625 mm, 0.833 mm,
1.25 mm, 1.25 mm or 2.5 mm in VariSeed, and 1 mm, 1.67 mm and 5 mm in MIM Symphony.
Generally, the Z resolution is set to match the through-plane resolution of the acquired
images, that is, 2.5 mm CT slice thicknesses for post-implant plans. In this study, since
I wanted to compare MIM Symphony to our clinical standard at that time (VariSeed
with 2.5 mm Z resolution), the closest Z resolution (1.67 mm) was used in MIM Symphony.
Nevertheless, for general use of MIM Symphony, I recommend the Z resolution to be at the
smallest available setting, that is, 1 mm, for greater calculation accuracy.
Another limitation is that unlike the prostate, the bladder and rectum are partially
contoured because these anatomical structures are not fully covered in the imaging field of
view on the ultrasound imaging system. This amplified the volume calculation differences
between VariSeed and MIM Symphony. Therefore, if importing plans from VariSeed, I
caution users to carefully evaluate the contours. The contour issues will not be present if
the entire treatment planning is done with the MIM Symphony TPS.
Also, note that the bladder was evaluated instead of the urethra. For prediction of
urinary complications, the urethra is a better indicator.56 A foley catheter is generally used
to visualize the urethra on CT images due to the lack of soft tissue contrast between the
urethra and the prostate. However, apart from causing discomfort to patients, the placement
of the foley catheter in the urethra can distort dose distribution artificially.84 Therefore,
unless specifically indicated, a foley catheter is not used for Day 30 post-implant imaging.
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Since urethra contours were not available for most patients, bladder contours were used for
evaluation in this study.
2.5.3 Implications
MIM Symphony can be used as an alternative to VariSeed for the clinical treatment planning
of LDR prostate brachytherapy and for post-implant dosimetric evaluation. Specifically for
our purposes, MIM Symphony allows the import of MRI images of patients implanted with
the Sirius MRI markers. In Chapters 3 to 5, I present the various components involved in
MRI image acquisition for post-implant dosimetry.
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ker, M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan,
and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl
cysteine (C4) contrast agent marker for prostate brachytherapy”. In:
Phys Med Biol 59.10 (2014), pp. 2505–1657 ( c©Institute of Physics and
Engineering in Medicine. By permission of IOP Publishing. All rights
reserved).
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3.1 Background
3.1.1 Basic MRI Contrast Mechanism
Contrast on MRI images is generated through the magnetic resonance of hydrogen atoms in
different tissues of the body.85 A hydrogen atom, with only one proton, has a non-zero net
magnetic moment.85 When in an external magnetic field B0, the hydrogen precess at the
Larmor frequency ω0 according to the Larmor equation
ω0 = γB0 (3.1)
where γ is the gyromagnetic ratio (γ = 42.58 MHz/T for hydrogen).85 Each hydrogen atom
will either precess along or opposite to B0 (defined in the z-direction), but more hydrogen
atoms will align along B0 since this is a lower energy state.
85 The sum of all the hydrogen
atoms’ alignment vectors, or net magnetization vector, at equilibrium is M0.
85 Different
tissues have different signal intensities on MRI images because of the varying hydrogen
contents of the tissues.85 To probe this, a radiofrequency (RF) pulse is applied to move the
magnetization vector M away from B0.
85 However, M recovers to M0 to the equilibrium
state over time.85 This timing is governed by spin-lattice relaxation time T1 and spin-spin
relaxation time T2.
85
3.1.2 Spin-lattice Relaxation Time T1
As depicted by Figure 3.1, the spin-lattice relaxation is when the longitudinal component of
the magnetization vector, Mz recovers towards equilibrium with its surroundings (lattice)
according to
Mz(t) = M0(1− exp(−t/T1)) (3.2)
Image contrast can be generated by emphasizing the differences in T1 of various tissues,
by adjusting scan parameters, such as repetition time (TR) and echo time (TE) that control
image weighting.85 For instance, a conventional T1-weighted spin echo sequence will have
short TR and short TE (Figure 3.2).
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Figure 3.1: After a 90-degree pulse, Mz is converted from a maximum value at equilibrium
to Mz = 0. Return of Mz to equilibrium occurs exponentially and is characterized by the
spin-lattice T1 relaxation constant. After an elapsed time equal to T1, 63 % of the longitudinal
magnetization is recovered. Spin-lattice recovery takes longer than spin-spin decay (T2).
Reprinted from Jerrold T. Bushberg. The essential physics of medical imaging. 3rd ed.
Philadelphia: Lippincott Williams and Wilkins, 201285 (license number: 3876590155681).
Figure 3.2: T1-weighted contrast: Longitudinal recovery (left) and transverse decay (right)
diagrams (note the values of the x-axis time scales) show four brain tissues and T1 and T2
relaxation constants. T1-weighted contrast requires the selection of a TR that emphasizes
the differences in the T1 characteristics of the tissues (e.g., TR = ∼ 500 ms), and reduces the
T2 characteristics by using a short TE so that transverse decay is reduced (e.g., TE ≤ 15 ms).
Reprinted from Jerrold T. Bushberg. The essential physics of medical imaging. 3rd ed.
Philadelphia: Lippincott Williams and Wilkins, 201285 (license number: 3876590155681).
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Figure 3.3: The loss of Mxy phase coherence occurs exponentially caused by intrinsic spin-
spin interactions in the tissues and extrinsic magnetic field inhomogeneities. The exponential
decay constant, T2 is the time over which the signal decays to 37 % of the initial transverse
magnetization (e.g., after a 90-degree pulse). Reprinted from Jerrold T. Bushberg. The
essential physics of medical imaging. 3rd ed. Philadelphia: Lippincott Williams and Wilkins,
201285 (license number: 3876590155681).
Figure 3.4: T2 weighted contrast requires the use of a long TR (e.g., greater than 2000 ms) to
reduce T1 influences, and a long TE (e.g., greater than 80 ms to allow for T2 decay to evolve.
Compared to the proton density weighting, the difference is with longer TE. Reprinted
from Jerrold T. Bushberg. The essential physics of medical imaging. 3rd ed. Philadelphia:
Lippincott Williams and Wilkins, 201285 (license number: 3876590155681).
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3.1.3 Spin-spin Relaxation Time T2
As depicted by Figure 3.3, the spin-spin relaxation is when the transverse component of the
magnetization vector Mxy decays towards equilibrium. Usually the RF pulse used flips the
magnetization vector M 90◦ into the x-y plane. Mxy decays exponentially due to loss of
phase coherence due to spin-spin interactions according to
Mxy(t) = Mxy(0) exp(−t/T2) (3.3)
where Mxy(0) is the net transverse magnetization immediately after the RF pulse.
Image contrast can also be generated by emphasizing the differences in T2 of various
tissues, by adjusting scan parameters, such as TR and TE.85 For instance, a conventional
T2-weighted spin echo sequence will have long TR and long TE (Figure 3.4).
Another factor for the loss of phase coherence is due to B0 inhomogeneities, ∆Bi.
Therefore, the observed decay of transverse magnetization would be faster than predicted by
T2 effects alone (Figure 3.5). This observed T2 is denoted T
∗
2 , whereby
1
T ∗2
=
1
T2
+
1
γ∆Bi
(3.4)
Figure 3.5: T2 is the decay time resulting from intrinsic magnetic properties of the sample.
T ∗2 is the decay time resulting from both intrinsic and extrinsic magnetic field variations.
T2 is always longer than T
∗
2 . Reprinted from Jerrold T. Bushberg. The essential physics of
medical imaging. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 201285 (license
number: 3876590155681).
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3.1.4 Contrast agents
Contrast agents can be used when the generated MRI images have insufficient contrast.65 The
ions in contrast agents relax nearby water protons, thereby affecting T1 and T2.
25 Positive
contrast agents shorten the T1 of these water protons, leading to more rapid magnetization
recovery and higher signal. For example, following injection of a gadolinium into the body,
the gadolinium travels along blood vessels and if the blood-brain-barrier is compromised,
the gadolinium leaks into and enhances (by T1-shortening) the tissue it accumulates in.86
Conversely, negative contrast agents shorten the T2, leading to increased dephasing of the
transverse signal and lower signal. The capacity of contrast agents to shorten the relaxation
times of bulk water protons is defined as relaxivity.87
3.2 Purpose
Intrinsic parameters (such as T1, T2 and T
∗
2 ) and scan parameters (such as TR and TE)
affect the signal on MRI images, hence knowing these parameters is crucial for developing
an appropriate post-implant MRI protocol.88,89 The improved soft tissue contrast on MRI
compared to CT is provided by the variations in T1 and T2, compared to x-ray attenuation.
90
The Sirius MRI marker introduced in Section 1.7 contains the C4 contrast agent. Previously,
the C4 contrast agent’s MRI relaxation characteristics had not been characterized. In this
chapter, I describe the determination of the relaxation characteristics of the C4 contrast
agent. Using common imaging sequences, I measured relaxation times, relaxation rates, and
relaxivities at two standard clinical field strengths (1.5 T and 3.0 T), for three conventional
scan planes (coronal, sagittal, and axial), and at two temperatures (room temperature and
body temperature).
3.3 Methods
3.3.1 Data Collection
In the current study, the C4 contrast agent was obtained by dissolving CoCl2 · 6H2O (cobalt
dichloride hexahydrate) and NAC (N-acetyl-L-cysteine) in water. Keeping the concentration
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Table 3.1: Conversion from weight percentages to millimolar (mm) for various concentrations
of cobalt dichloride. Reproduced from T. Y. Lim, R. J. Stafford, R. J. Kudchadker,
M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan, and S. J. Frank. “MRI
characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate
brachytherapy”. In: Phys Med Biol 59.10 (2014), pp. 2505–1657 ( c©Institute of Physics and
Engineering in Medicine. Reproduced by permission of IOP Publishing. All rights reserved).
Weight Percentage (%) Concentration (mm)
0.0 0.00
0.1 4.229
0.2 8.458
0.5 21.145
1.0 42.290
1.5 63.435
2.0 84.580
5.0 211.450
of NAC in the solution fixed at 2 %, the concentration of cobalt dichloride was varied to be
0.1 %, 0.2 %, 0.5 %, 1.0 %, 1.5 %, 2.0 %, or 5.0 %∗. To match the standard unit for relaxivity
(mm−1 s−1), the weight percentages were converted into millimolar (mm), presented in Table
3.1.
The solutions were separated by cobalt dichloride concentration into seven cylindrical
glass vials. Two additional vials, one filled only with water and another filled only with
2.0 % NAC, were used as controls. The nine vials were placed in a thin transparent plastic
cup and arranged as shown in Figure 3.6. The plastic cup was then affixed to the center of
a cylindrical plastic container. Water was poured into the space between the plastic cup
and the container to reduce susceptibility artifacts. The container with the nine samples
was then centered in a receive-only head array for reception with the body coil used for
excitation.
I investigated the dependence of relaxation on three parameters: field strength, orien-
tation, and temperature. For field strength dependence measurements, the samples were
scanned using a 1.5 T and a 3.0 T clinical MRI scanner (Excite HDxt and Discovery MR750
respectively; GE Healthcare, Waukesha, WI). For orientation dependence measurements,
the samples were positioned such that the base of the vials were parallel to the chosen scan
plane (coronal, sagittal, or axial). For temperature dependence measurements, the samples
∗All stated percentages are weight percentages
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Figure 3.6: Nine glass vials with increasing concentrations of cobalt dichloride, arranged in
a clockwise fashion. The center vial contained water only and the top vial contained 2.0 %
N-acetyl-L-cysteine (NAC) only; the remaining vials contained 2 % NAC and 0.1 %, 0.2 %,
0.5 %, 1.0 %, 1.5 %, 2.0 %, or 5.0 % cobalt dichloride. Reproduced from T. Y. Lim, R. J.
Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan,
and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast
agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10 (2014), pp. 2505–1657
( c©Institute of Physics and Engineering in Medicine. Reproduced by permission of IOP
Publishing. All rights reserved).
were placed in a water bath at room temperature (20.3 ◦C as denoted on the console) or
body temperature (37± 1 ◦C).
Analysis was performed oﬄine using Matlab 7.9.0. (The MathWorks, Inc., Natick, MA).
A square 7-pixel × 7-pixel region-of-interest (ROI) was defined in the center of each vial
on the image, away from the vial edges to prevent signal inhomogeneity. The mean and
standard deviation of the signal within the ROI were recorded at each time point.
3.3.2 Measuring Spin-lattice Relaxation Time T1
T1 measurements were obtained using a single-slice inversion recovery spin echo sequence,
which is the pulse sequence most commonly used for T1 determination. At 1.5 T, I used the
following parameters: TI = 50 ms, 100 ms, 200 ms, 400 ms, 800 ms, 1600 ms, 3200 ms; matrix
size = 128× 128; FOV = 16 cm; TR/TE = 5000/10 ms; bandwidth = ±122.109 kHz; NEX
= 0.5; and slice thickness = 10 mm. At 3.0 T, I used the following parameters: TI = 50 ms,
100 ms, 200 ms, 400 ms, 800 ms, 1600 ms, 3200 ms; matrix size = 256× 256; FOV = 16 cm;
TR/TE = 5000/10 ms; bandwidth = ±62.50 kHz; NEX = 5.0; and slice thickness = 5 mm.
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The signal for inversion recovery is typically expressed as
S = M0(1− 2 exp(−TI/T1) + exp(−TR/T1)) (3.5)
where M0 is the equilibrium magnetization, TI denotes inversion time, and TR denotes
repetition time. For a given concentration, at each TI, the signal was represented by
the mean signal in the ROI and the standard deviation was used to estimate uncertainty.
Because TR and M0 were fixed, I estimated T1 using the Levenberg-Marquardt least-squares
algorithm.91,92 For each ROI defined in each vial, I used the time point with the lowest
signal as our initial estimate for T1, which ideally should be close to the null point. However,
T1 was expected to be extremely close to 0 at higher concentrations (1.5 %, 2.0 % and 5.0 %
for 1.5 T, and 5 % for 3.0 T), so to ensure stability for these points, I used 10 ms for some of
the initial estimates for T1.
3.3.3 Measuring Spin-spin Relaxation Time T2
T2 measurements were obtained using a 2D spin-echo sequence. At 1.5 T, I used the following
parameters: TR = 1000 ms; TE = 10 ms, 20 ms, 30 ms, 40 ms, 50 ms, 60 ms, 70 ms, 80 ms,
90 ms, 100 ms, 150 ms, 200 ms, 250 ms, 300 ms, 350 ms, 400 ms, 500 ms, 600 ms; matrix size
= 128× 128; bandwidth = ±122.109 kHz; FOV = 16 cm; NEX = 0.5; and slice thickness
= 10 mm. At 3.0 T, I used the following parameters: TR = 5000 ms; TE = 10 ms, 20 ms,
30 ms, 40 ms, 50 ms, 60 ms, 70 ms, 80 ms; matrix size = 256× 128; bandwidth = ±62.5 kHz;
FOV = 6 cm; NEX = 1; and slice thickness = 10 mm.
I fit the measured echo amplitudes to
S = M0 exp(−TE/T2) (3.6)
For each ROI, a first-degree polynomial fitting was performed on the spin echo signals
plotted against time to obtain the initial estimate for T2.
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(a) (b)
Figure 3.7: Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at 1.5 T and
3.0 T, for various cobalt dichloride concentrations. Reproduced from T. Y. Lim, R. J.
Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan,
and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast
agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10 (2014), pp. 2505–1657
( c©Institute of Physics and Engineering in Medicine. Reproduced by permission of IOP
Publishing. All rights reserved).
3.3.4 Measuring Relaxivities r1 and r2
Starting with the initial T1 and T2 estimates, I applied nonlinear regression to the signal
plotted against each inversion/echo time and iteratively applied the least-squares method to
estimate T1 and T2. Relaxivity was defined as the change in relaxation rate of bulk water
per unit concentration of cobalt dichloride. The relaxation rates were calculated and plotted
against cobalt dichloride concentration. Thus, the slopes from the linear fit to this plot
result in relaxivity values r1 and r2.
3.4 Results and Discussion
3.4.1 Effect of Field Strength
T1 and T2 values measured at 1.5 T and 3.0 T, for cobalt dichloride concentrations ranging
from 0 mm to 211.45 mm, are shown in Figure 3.7. Corresponding relaxation rates are shown
in Figure 3.8.
The T1 values were similar at both field strengths, even across different cobalt dichloride
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(a) (b)
Figure 3.8: Spin-lattice relaxation rate R1 = 1/T1 and spin-spin relaxation rate R2 = 1/T2
at 1.5 T and 3.0 T, for various cobalt dichloride concentrations. The relaxivity (mm−1 s−1)
was determined by the slope from a linear fit of relaxation rate (s−1) plotted against
cobalt dichloride concentration (mm). Reproduced from T. Y. Lim, R. J. Stafford, R.
J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan, and
S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast
agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10 (2014), pp. 2505–1657
( c©Institute of Physics and Engineering in Medicine. Reproduced by permission of IOP
Publishing. All rights reserved).
concentrations. As field strength increases, the corresponding Larmor frequency increases;
hence the energy transfer to the lattice is less efficient. Thus, increased T1 values are
expected at high field strengths, and I did observe this slight increase in T1 at the lower
concentrations of cobalt dichloride. However, the T1 values at the two field strengths agreed
well overall. Hence, the C4 contrast agent’s r1 relaxivity values obtained at the two different
field strengths were similar, suggesting that r1 is not dependent on field strength.
However, the T2 values of the C4 contrast agent at 3.0 T were slightly lower than at 1.5 T,
translating to consistently higher spin-spin relaxation rates. In other words, the T2 values at
3.0 T decreased at a greater rate with increasing concentration compared with that at 1.5 T.
Therefore, the value of the slope, which corresponds directly to the r2 of C4 contrast agent,
was higher at 3.0 T than at 1.5 T, suggesting that r2 is dependent on field strength and that
T2 is likely to decrease with increasing field strengths. Although the spin-spin relaxivity
(r2) is higher at 3.0 T than at 1.5 T, the MRI signal intensity is still dependent on the pulse
sequence chosen. The higher r2 values at higher field strengths simply reaffirm the increased
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(a) (b)
Figure 3.9: Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at three
different vial orientations, for various cobalt dichloride concentrations. Reproduced from
T. Y. Lim, R. J. Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao,
K. S. Martirosyan, and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl
cysteine (C4) contrast agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10
(2014), pp. 2505–1657 ( c©Institute of Physics and Engineering in Medicine. Reproduced by
permission of IOP Publishing. All rights reserved).
T2-lowering ability, with the same considerations as stated before. Overall, because r1 is not
dependent on field strength, the increase in r2 with field strength increases the relaxivity
ratio r2/r1.
For cobalt dichloride concentrations< 1% (42.49 mm), simply increasing the concentration
to enhance the signal is not feasible because the shorter T2 values at 3.0 T reduces the effect
of T1-shortening. For cobalt dichloride concentrations > 1%, increasing the concentration
further offers little gain because the T1-shortening effect plateaus. Thus, the concentration
of 1% cobalt dichloride offered a reasonable compromise of the T1 and T2 changes at the
two clinically relevant field strengths to generate a strong signal. The 10% cobalt dichloride
marker placed adjacent to the radioactive seed was shown to result in greater radiation dose
perturbations (Figure 1.10), and subsequently greater impact on DVH parameter, compared
to the 1% marker and a conventional spacer (this study was performed using the glycine
instead of NAC as the chelator). Both 1% and 10% cobalt dichloride in the C4 contrast
agent is a low concentration that has been shown to be safe for clinical use.77
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(a) (b)
Figure 3.10: Spin-lattice relaxation rate R1 = 1/T1 and spin-spin relaxation rate R2 = 1/T2
at three different vial orientations, for various cobalt dichloride concentrations. The relaxivity
(mm−1 s−1) was determined by the slope from a linear fit of relaxation rate (s−1) plotted
against cobalt dichloride concentration (mm). Reproduced from T. Y. Lim, R. J. Stafford,
R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao, K. S. Martirosyan, and
S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast
agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10 (2014), pp. 2505–1657
( c©Institute of Physics and Engineering in Medicine. Reproduced by permission of IOP
Publishing. All rights reserved).
3.4.2 Effect of Orientation
The T1 and T2 values measured at coronal, sagittal, and axial orientations are shown in
Figure 3.9, and Figure 3.10 shows the relaxation rates across different cobalt dichloride
concentrations. No significant differences in relaxation measurements were observed across
different orientations of the vial with respect to the main magnetic field.
Brachytherapy seeds have been shown to have artifacts that are dependent on the seeds’
orientation with respect to the main magnetic field.93 The main purpose of studying the
effects of orientation on the relaxation characteristics of the C4 contrast agent is to detect
any possible MR artifacts. When the Sirius MRI marker encapsulating the C4 contrast agent
is implanted into the prostate, the Sirius MRI markers could potentially tilt in any direction.
In the present study, the relaxation times, relaxation rates, and relaxivities, which are
intrinsic to the cobalt dichloride complex, were similar for all three orientations. Therefore,
when imaging the Sirius MRI marker, the investigation of the origin of any detected artifacts
would be best directed toward scrutinizing extrinsic parameters.
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(a) (b)
Figure 3.11: Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at room
temperature and body temperature, for various cobalt dichloride concentrations. Reproduced
from T. Y. Lim, R. J. Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A.
Rao, K. S. Martirosyan, and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl
cysteine (C4) contrast agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10
(2014), pp. 2505–1657 ( c©Institute of Physics and Engineering in Medicine. Reproduced by
permission of IOP Publishing. All rights reserved).
3.4.3 Effect of Temperature
Figure 3.11 shows the T1 and T2 measured at room temperature and body temperature,
and Figure 3.12 shows the corresponding relaxation rates across different cobalt dichloride
concentrations. T1 was similar at both room temperature and body temperature for all cobalt
dichloride concentrations investigated. Therefore, the corresponding relaxation rates were
similar for the two temperatures as well, suggesting that r1 is not dependent on temperature.
Conversely, the T2 of the C4 contrast agent at body temperature was slightly higher
than at room temperature, translating to lower spin-spin relaxation rates. Therefore, the
value of the slope, which corresponds directly to the r2 of the C4 contrast agent, was lower
at body temperature than at room temperature. These temperature data sets suggest that
r2 is dependent on temperature and that T2 is likely to increase with increasing temperature.
Because r1 is not dependent on temperature, the decrease in r2 with temperature decreases
the relaxivity ratio r2/r1.
Theoretically, as temperature increases, the correlation time for the interaction decreases,
requiring longer relaxation times and causing relaxation rates to lower, thereby resulting
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(a) (b)
Figure 3.12: Spin-lattice relaxation rate R1 = 1/T1 and spin-spin relaxation rate R2 = 1/T2
at room temperature and body temperature, for various cobalt dichloride concentrations.
The relaxivity (mm−1 s−1) was determined by the slope from a linear fit of relaxation
rate (s−1) plotted against cobalt dichloride concentration (mm). Reproduced from T. Y.
Lim, R. J. Stafford, R. J. Kudchadker, M. Sankaranarayanapillai, G. Ibbott, A. Rao,
K. S. Martirosyan, and S. J. Frank. “MRI characterization of cobalt dichloride-N-acetyl
cysteine (C4) contrast agent marker for prostate brachytherapy”. In: Phys Med Biol 59.10
(2014), pp. 2505–1657 ( c©Institute of Physics and Engineering in Medicine. Reproduced by
permission of IOP Publishing. All rights reserved).
in a decrease in relaxivity.94 In this study, for cobalt dichloride concentration of 1 %, the
change in T1 was not significant, whereas T2 was slightly longer at body temperature.
3.5 Conclusion
3.5.1 Summary
Relaxivity measurements of the C4 contrast agent at different field strengths, orientations
and temperatures are presented in Table 3.2.
T1 and T2 values can be affected by the presence of positive contrast agents. The
greater the concentration of cobalt dichloride ions, the smaller the T1 and T2 relaxation
times. Consistent with our expectations from previous investigations,20 the T1-shortening
effect of the C4 contrast agent was very dominant; therefore, a very high signal (positive
enhancement) from the C4 contrast agent against the prostatic background was expected.
Because of the innate fast transverse relaxation of prostate tissue, the T2 shortening effect
was not as strong as the T1 shortening effect.
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Table 3.2: Relaxivities r1 and r2 for different field strengths, orientations, and temperatures.
Reprinted from T. Y. Lim, R. J. Stafford, R. J. Kudchadker, M. Sankaranarayanapillai,
G. Ibbott, A. Rao, K. S. Martirosyan, and S. J. Frank. “MRI characterization of cobalt
dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy”. In:
Phys Med Biol 59.10 (2014), pp. 2505–1657 ( c©Institute of Physics and Engineering in
Medicine. Reproduced by permission of IOP Publishing. All rights reserved).
r1 (mm
−1 s−1) r2 (mm−1 s−1)
Field Strength
1.5 T 0.158 ± 0.003 0.208 ± 0.002
3.0 T 0.148 ± 0.002 0.328 ± 0.006
Orientation
Coronal 0.145 ± 0.001 0.300 ± 0.005
Sagittal 0.144 ± 0.002 0.315 ± 0.006
Axial 0.149 ± 0.001 0.324 ± 0.005
Temperature
20.3 ◦C 0.144 ± 0.002 0.337 ± 0.005
37.0 ◦C 0.127 ± 0.002 0.186 ± 0.001
Gadolinium-based contrast agents are the most commonly used contrast agents.95 At
1.5 T and 3.0 T, the measured relaxivities in water for gadolinium-based contrast agents
range from 3 mm−1 s−1 to 5 mm−1 s−1.95 The relaxivities measured for the C4 contrast
agent ranged from 0.1 mm−1 s−1 to 0.4 mm−1 s−1, implying a weaker efficiency in influencing
tissue relaxation rates compared with gadolinium-based contrast agents. Cobalt has three
unpaired electrons, whereas gadolinium has seven unpaired electrons. Therefore, a higher
concentration of cobalt is needed to achieve the same influence as gadolinium. However,
the C4 contrast agent remains in the polymer casing with no tissue uptake, because the
main indication for the Sirius MRI marker is an encapsulated C4 contrast agent marker to
enable more accurate localization of brachytherapy seeds. Moreover, the C4 contrast agent
is associated with negligible toxicity,77 enabling the use of very high concentrations to reach
sufficient T1-shortening effects and induce positive contrast. The concentration of gadolinium
is limited by the potential for inducing toxicity, such as nephrogenic systemic fibrosis in
patients with impaired renal function. Similar to gadolinium-based contrast agents, the
spin-lattice and spin-spin relaxivities for the C4 contrast agent are approximately the same,
suggesting the same T1- or T2-shortening capability. Hence, the C4 contrast agent could
potentially be used as both a positive and a negative contrast agent.
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3.5.2 Limitations
A limitation of this study is that I evaluated the effects of only two different temperatures
on relaxation: room temperature and the more clinically relevant body temperature. Any
extrapolation of our findings to storage ambient temperature concerns or non-medical use
warrants further investigation.
3.5.3 Implications
The relaxation values obtained indicate that the C4 contrast agent is promising for encapsu-
lation as the contrast agent in Sirius MRI markers that may allow MRI-only post-implant
dosimetry.
Using specific pulse sequences, such as T1-weighted or T2-weighted sequences, can enhance
the differences in signal intensities of various tissues. With knowledge of the relaxation
times of the desired contrast agent concentration, I can adjust pulse sequence parameters to
provide greater contrast between the Sirius MRI marker and surrounding tissue. In the next
chapter, I will describe a phantom investigation into the effects of scan parameter variations
on the visibility of Sirius MRI markers.
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4.1 Background
4.1.1 Spoiled Gradient Echo Sequences
A pulse sequence is a sequence of RF and gradient pulses with predefined pulse lengths and
amplitudes that affect signal generation and reception. A pulse sequence with the optimal
combination of pulse sequence parameters needs to be defined to obtain high marker visibility
while balancing against other conflicting factors (such as image acquisition time, spatial
resolution, and image artifacts) to provide the best images for post-implant dosimetry, given
the significant time and cost associated with MRI.
Two main classes of pulse sequences are the spin echo sequence97 and the gradient echo
sequence. Spin echoes are produced by two RF pulses, but gradient echoes are produced
with a single RF pulse together with gradient manipulation.98 Using a gradient echo pulse
sequence enables shorter TR and TE values, therefore reducing image acquisition time.
The commonly cited drawback of gradient echo pulse sequences is increased susceptibility
artifacts; but for post-implant dosimetry, the susceptibility artifact from the seeds result in
a characteristic dumbbell appearance that could potentially be used to more definitively
locate the seeds based on the distinct susceptibility patterns∗. T1-weighted gradient echo
sequences have been reported to yield the best seed visibility.27
Spoiled gradient echo sequences are gradient echo sequences with a spoiling mechanism
(such as radiofrequency-spoiled) that disrupts transverse coherences that previously persisted,
thereby ensuring no transverse coherences immediately before each RF pulse. Different
scanner manufacturers have different terms for this sequence: GE = radiofrequency-spoiled
gradient recalled echo (SPGR), Siemens = Fast Low Angle SHot (FLASH) while Philips =
Fast Field Echo (T1-FFE).
The spoiled gradient echo signal equation is
ρˆ = ρ0 sinα
1− exp(−TR/T1)
1− exp(−TR/T1) cosα exp(−TE/T
∗
2 ) (4.1)
∗See Section 5.1.4 on other pulse sequences that take advantage of the seed susceptibility artifact for seed
localization.
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(a) (b)
(c) (d)
Figure 4.1: Signal trends predicted from Equation 4.1. (a) Relative signals of the Sirius MRI
marker and prostate for varying TR, and (b) zoomed view illustrates the signal difference
between Sirius MRI marker and prostate using short TR, (c) relative signals of the Sirius
MRI marker and prostate for varying TE given very long TR, and (d) relative signals of the
Sirius MRI marker and prostate for varying TE given short TR.
4.1.2 Pulse Sequence Parameters
Repetition Time The repetition time is the time from the application of an RF excitation
pulse to the repeated application of the RF excitation pulse.85 When imaging at 3.0 T, at
sufficiently long TR (> 3600 ms given Sirius MRI marker and prostate estimated relaxation
times[57, 99]), the estimated Sirius MRI marker signal becomes lower than the estimated
prostate signal (Figures 4.1a and 4.1c), which would result in the markers appearing
hypointense against the prostatic tissue. For T1-weighted sequences using short TR (Figure
4.1b) and short TE (Figure 4.1d), the differences in T1 would be emphasized.
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Figure 4.2: Signal trends of the Sirius MRI marker and prostate for varying flip angle,
predicted from Equation 4.1.
Echo Time The echo time is the time from the application of an RF excitation pulse to
the peak of the echo.85 Shown in Figure 4.1 are the signal trends predicted from Equation 4.1
given the Sirius MRI marker and prostate estimated relaxation times57,99 (using T2 instead of
T ∗2 ). When imaging at 3.0 T, due to the relatively short T2, the TE used must be sufficiently
short (< 8.3 ms† given Sirius MRI marker and prostate estimated relaxation times57,99), else
the estimated Sirius MRI marker signal becomes lower than the estimated prostate signal,
which would result in the markers appearing hypointense against the prostatic tissue.
Flip angle The flip angle (α) is the angle at which the magnetization vector is flipped
from the longitudinal axis of the main magnetic field. Using relaxation times for the Sirius
MRI marker’s contrast agent57 and for prostate99 to estimate the signal trend according to
Equation 4.1, the contrast separation is highest in the proximity of α = 16 deg to 20 deg
(Figure 4.2).
Number of Excitations The number of excitations (NEX) is the number of times the
scan is repeated and the repeated signals averaged.100
Bandwidth The receiver bandwidth (BW) is the signal sampling rate, so the faster the
signal is sampled, the wider the bandwidth.100
†The actual TE required would be much shorter because the estimated TE value was calculated using T2
instead of T ∗2 , so the TE required would be much shorter.
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Field of view The field of view (FOV) is the area from which the signal is sampled in
the defined scan plane. It may be specified in the frequency- and phase-encoding directions
on the image. In this study, the FOV refers to a square FOV (full phase FOV). For limited
gradient strength Gx and the proportional relationship between frequency and field strength
via the Larmor equation (Equation 3.1), FOV is directly proportional to BW via
FOVx = BW/(γGx) (4.2)
When the FOV decreases, the distance between the image’s edges decrease. Therefore, for
fixed BW (range of frequencies from one edge to the other edge of the image), decreasing
the FOV requires a stronger gradient.100
Slice thickness The slice thickness (∆z) defines the through-plane resolution.
Encoding steps The frequency-encoding steps (Nx) and phase-encoding steps (Ny) can
be transformed to the x and y dimensions, as spatial locations are encoded by varying
frequency and phase across the volume.100 Generally, encoding steps relates directly to the
number of acquisition pixels in the x and y directions, and defines the in-plane resolution.
4.2 Purpose
In the last chapter, the T1 and T2 of the C4 contrast agent was determined. The Sirius
MRI markers containing the C4 contrast agent can be visualized using the 3D FSPGR
sequence. However, the effects on the Sirius MRI marker due to pulse sequence parameter
variations should be quantified to allow the appropriate discernment in setting pulse sequence
parameters. To obtain the desired image contrast, the MRI user has the capability to
adjust several parameters of a pulse sequence, depending on the suitability to the specified
pulse sequence template file, variations in imaging technique implementation and hardware
performance limits.
To determine which parameters yield the most consistent and high-signal visualization of
the markers, I investigated several user-adjustable scan parameters of the 3D FSPGR sequence
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on a GE 3.0 T scanner in normal scanning mode. All markers were detected on images
acquired using the scan parameter combinations examined, but the extent of the marker
visibility and conspicuity varied depending on the selected scan parameter combinations.
I also reported the trends of scan times for varying pulse sequence parameters, as short
image acquisition time is a priority, sometimes even at the expense of spatial resolution and
contrast, to minimize patient motion artifacts. The pulse sequence parameters should be
chosen based on evaluating the trade-offs between marker visibility, scan time, resolution and
artifacts. I investigated the effects of varying α, NEX, BW, FOV, ∆z and Nx ×Ny on the
marker’s signal strength, image noise level, signal-to-noise ratio (SNR) and spatial resolution.
In addition, I noted relevant conflicting factors that may advise against using the parameter
value optimized for highest marker signal. A comprehensive and practical understanding of
the impact of scan parameter adjustments on image quality is important for the acquisition
of high-quality post-implant MRI scans for accurate dosimetric assessment.
4.3 Methods
4.3.1 Data Collection
A multi-modality prostate phantom Model 053-MM for ultrasound, CT and MRI (CIRS,
Norfolk, VA) was implanted with 66 MRI markers (Sirius; C4 Imaging, Houston, TX) and
86 dummy (non-radioactive) seeds in stranded seed-marker combination using 20 needles
(Figure 4.3). The phantom was imaged using a 3.0 T MRI scanner (GE Discovery MR750
with 50 mT/m amplitude and 200 T/m/s slew rate; GE, Waukesha, WI) and an 8-channel
torso coil (GE, Waukesha, WI) with a 3D FSPGR sequence, under various combinations of
scan parameters. The scan parameters varied here were α, NEX, BW, FOV, ∆z and Nx×Ny.
Echo time (TE) was optimized as the minimum achievable TE to acquire a full echo in
the frequency-encoding direction and repetition time (TR) was automatically minimized.
The marker signal as a function of each parameter of interest was systematically studied by
keeping all other parameters constant at baseline values (Table 4.1).
Image resolution refers to the pixel size of the output image. In-plane spatial resolution
depends on the FOV and number of encoding steps, while through-plane spatial resolution
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Figure 4.3: Materials used in the study. (a) Dummy seeds and MRI markers. (b) Seed-
marker strand. (c) Implanted CIRS multi-modality prostate phantom. (d) MRI scan of
the prostate phantom acquired with baseline scan parameters. (e) Zoomed-in view of the
prostate. The seeds appear as hypointense voids while markers appear as hyperintense
spots. (Scale denotes 1 cm.) Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J.
Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence
parameter selection on signal strength in positive-contrast MRI markers for MRI-based
prostate post-implant assessment”. In: Med Phys 43.7 (2016)96 (with permission from the
American Association of Physicists in Medicine).
depends on the slice thickness.
4.3.2 Image Processing
Image processing was performed in Matlab 8.1.0 (The Mathworks, Inc., Natick, MA). On
the magnitude reconstructed images, I recorded the maximum signal intensities for each
of the 66 markers to calculate the average and standard deviation of the marker signal
intensity. I plotted average marker signal against the various scan parameters, with error
bars denoting the marker signal standard deviation. I also recorded the standard deviation
of a 50× 50 (2500 pixels) rectangular region-of-interest without artifacts in air, per the
National Electrical Manufacturers Association (NEMA)101 image noise evaluation method
4. The SNR was calculated as the ratio of average marker signal intensity to the standard
deviation in air. I plotted marker SNR against the various scan parameters, with error
bars denoting propagated uncertainty from the marker signal. All signal, noise or SNR
values were normalized to the signal, noise or SNR values obtained using baseline imaging
parameters. I also plotted the (non-normalized) contrast-to-noise ratio (CNR) between
the average marker signal intensity to average prostate signal intensity, for various scan
parameters.
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Table 4.1: Scan parameters investigated (baseline values are bolded). Reprinted from T. Y.
Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and
S. J. Frank. “Effect of pulse sequence parameter selection on signal strength in positive-
contrast MRI markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7
(2016)96 (with permission from the American Association of Physicists in Medicine).
Scan Parameters Range of Values
α (◦) 4, 8, 12, 14, 16, 18, 20, 22, 30, 40, 50, 60
NEX a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25
BW (± kHz) 19.23, 31.25, 41.67, 50.00, 62.50, 83.33, 90.91, 100.00, 111.10, 125.00,
142.86
FOV (cm) b 8, 10, 12, 14, 16, 18, 20
∆z (mm) c 1.0, 1.2, 1.4, 1.6, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0
Nx ×Ny d 140× 140, 160× 160, 160× 256, 192× 192, 224× 224, 256× 160,
256× 192, 256× 224, 256 × 256, 320× 320, 320× 256, 384× 256,
384× 384, 512× 256, 512× 512
TE ms 2.3
TR ms 5.9
Scan time min 7.3
a Halved due to phase oversampling
b Square FOV
c Interpolated to half the specified ∆z
d Interpolated to 512× 512
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Figure 4.4: The effect of varying flip angle on the visual appearance of images. Reprinted
from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao,
G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal strength
in positive-contrast MRI markers for MRI-based prostate post-implant assessment”. In:
Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists in
Medicine).
4.3.3 Statistical Analysis
To determine whether there was a significant relationship between a certain scan parameter
versus signal, noise or SNR, I performed a linear regression t-test at significance level =
0.01 with the null hypothesis that the slope parameter of a simple linear regression model
was zero against the alternative hypothesis that the slope was not zero. The assumptions
made were that signal, noise, or SNR has a linear relationship to a certain scan parameter,
independent of the scan parameter, has the same probability distribution standard deviation,
and roughly normally distributed.
4.4 Results and Discussion
4.4.1 Varying Flip Angle
At very small and very large α, the Sirius MRI marker’s visibility was reduced, but appeared
more hyperintense at certain α (Figure 4.4). In the following sections, the effect of α on
several image quality considerations for post-implant dosimetry purposes is illustrated.
Signal The signal of the Sirius MRI marker is strongly dependent on α, following the
trend predicted by the spoiled gradient recalled echo sequence equation (Equation 4.1).
The α that provided the highest marker signal was 14◦ (Figure 4.5a). The signals acquired
at α = 12◦ (angle providing greatest signal) and α = 14◦ (angle providing greatest SNR)
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(a) (b)
(c) (d)
(e) (f)
Figure 4.5: The effect of varying flip angle α on: (a) normalized Sirius MRI marker signal, (b)
normalized image noise, (c) normalized Sirius MRI marker signal-to-noise ratio (SNR), (d)
contrast-to-noise ratio (CNR) between the Sirius MRI marker and the prostate in phantom,
(e) echo time TE and repetition time TR, (e) scan times. Adapted from T. Y. Lim, R. J.
Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank.
“Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI
markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
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were not significantly different (p = 0.4799). The measured α that provided the greatest
signal was not significantly lower than the theoretical αE = (16.48± 1.08)◦ (p = 0.2538).
The lower signal measurements (Figure 2a) may be due to non-uniform excitation, that is,
radiofrequency field inhomogeneity leading to spatial variation of the flip angle.
Noise Noise was not significantly affected by α (slope = -0.0019, p = 0.0554) (Figure
4.5b).
Signal-to-noise ratio Owing to the constancy in noise levels across varying α, the
marker’s SNR reflects the measured marker signal, and the α that provided the highest
marker SNR was 12◦ (Figure 4.5c).
Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.5d).
Timing TE, TR, and scan time were longer at larger α (Figure 4.5f). Smaller α, characteris-
tic of gradient echo sequences, allows for shorter TR and thus shorter scan times (Figure 4.5f).
Contrast agents, such as that encapsulated in the marker, interact with nearby hydrogen
protons, facilitating the magnetization recovery of the hydrogen protons and shortening the
T1 of the material, resulting in a bright appearance on T1-weighted images.
102 Together with
TR and the intrinsic T1, α affects the extent of T1-weighting. For α < 12
◦, the marker signal
falls off very quickly, and becomes similar in signal intensity to the prostate, making the
markers less conspicuous (Figure 4.4); hence I do not recommend using α < 12◦. Conversely,
for α > 12◦, the reduced regrowth of the longitudinal magnetization may have reduced
the signal, but even at very large flip angles, the marker signal remained higher than the
prostate signal such that the markers can still be visualized (Figure 4.4). Since noise and
scan time are similar across the range of α investigated, the selection of a suitable α is mainly
motivated by increasing Sirius MRI marker signal. Therefore, for mean signal reduction of
no more than 10 % of the maximum Sirius MRI marker signal, I recommend not using α >
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20◦.
4.4.2 Varying Number of Excitations
With increasing NEX, the Sirius MRI marker’s visibility increased and the image appeared
less noisy (Figure 4.6). In the following, the effect of NEX on several image quality
considerations for post-implant dosimetry purposes is illustrated.
Signal The average signal was not significantly affected by varying NEX (slope = -0.0022,
p = 0.0188), except at NEX = 1 where the signal was lower (Figure 4.7a). However, since I
selected the phase-oversampling option (doubled Ny to reduce wrap artifact
‡), NEX was
reduced by half to preserve scan time. The signal drop at NEX = 1 (Figure 4.7a) was most
likely due to phase-oversampling requiring the use of fractional NEX imaging where only
about half of k-space was sampled.
Noise The average noise was reduced by 1/
√
NEX (Figure 4.7b), except at NEX = 1
(most likely due to phase-oversampling). Noise reduction with greater NEX is consistent
with theory.100
Signal-to-noise ratio SNR was thus improved by
√
NEX (Figure 4.7c). SNR increase
with greater NEX is consistent with theory.100
Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.7d).
Timing Varying NEX did not affect TE and TR (Figure 4.7f). However, since NEX is the
number of times the scan is repeated, scan time proportionally increases with NEX (Figure
4.7f).
‡See Section 4.4.4 and 4.14 for discussion of the wrap artifact
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Figure 4.6: The effect of varying number of excitations on the visual appearance of images.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan,
A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal
strength in positive-contrast MRI markers for MRI-based prostate post-implant assessment”.
In: Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists
in Medicine).
Artifacts Even though the signal using more NEX is greater, it may not be clinically
feasible, as the lengthened scan time increases the likelihood of patient motion artifacts.
Very high NEX (NEX ≥ 15) has diminishing returns, whereby further increases in NEX did
not yield significant gain in SNR but scan time still scaled proportionally. Limiting to scan
times under 10 minutes, I recommend using NEX ≤ 10.
4.4.3 Varying Bandwidth
At narrower BW, the image appeared less noisy and the Sirius MRI marker is more visible
albeit shifted (Figure 4.8). In the following, the effect of BW on several image quality
considerations for post-implant dosimetry purposes is illustrated.
Signal For BW≥ 244.14 Hz/pixel, the signal increased with√BW; for BW< 244.14 Hz/pixel,
the measured signal was greater than expected, with increasing signal at smaller BW until
162.77 Hz/pixel, then decreasing signal at smaller BW (Figure 4a). For narrow BW (BW
< 162.77 Hz/pixel), the sampling time was longer and the TE required was longer (Figure
4c), resulting in more T2 decay and the subsequent drop in signal (Figure 4.9a). Theoreti-
cally,100 signal increases with
√
BW. Since bandwidth is the signal sampling rate, at smaller
bandwidth, the sampling time is longer, and the TE required is longer, resulting in more T2
decay, hence lower signal. However, for BW < 244.14 Hz/pixel, the measured signal being
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(a) (b)
(c) (d)
(e) (f)
Figure 4.7: The effect of varying number of excitations on: (a) normalized Sirius MRI
marker signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise
ratio (SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the
prostate in phantom, (e) echo time TE and repetition time TR, (e) scan times. Adapted
from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao,
G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal strength
in positive-contrast MRI markers for MRI-based prostate post-implant assessment”. In:
Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists in
Medicine).
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Figure 4.8: The effect of varying bandwidth on the visual appearance of images. Both
the chemical shift artifact (black arrows) and seed susceptibility artifact (white arrows)
were reduced with increasing bandwidth. Reprinted from T. Y. Lim, R. J. Kudchadker,
J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank. “Effect of
pulse sequence parameter selection on signal strength in positive-contrast MRI markers for
MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96 (with permission
from the American Association of Physicists in Medicine).
greater than the theoretical prediction (Figure 4.9a) may be due to increased TR (Figure
4.9f).
Noise Narrower BW was associated with lower noise (Figure 4.9b). This is consistent
with the theory100 that narrower bandwidths allow less noise to pass through.
Signal-to-noise ratio SNR decreased with increasing BW and then leveled off starting at
244.14 Hz/pixel (Figure 4.9c). Theoretically,100 SNR is proportional to 1/
√
BW. However,
the measured SNR did not strictly follow the trendline depicted as the trendline did not
include variations in TE and TR at different BW. SNR was improved at narrower BW
(Figure 4.9c) mainly due to reduced noise, the effects of which may outweigh that of increased
T2 decay.
Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.9d).
Timing At BW < 162.77 Hz/pixel, increasing BW decreased TE (Figure 4.9f). At BW <
244.14 Hz/pixel, increasing BW decreased TR and scan times, while at BW≥ 244.14 Hz/pixel,
increasing BW increased TR and scan times. Images acquired with narrow BW had high
SNR (Figure 4.9c), but long scan times (Figure 4.9f). Scan times were < 10 minutes for
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(c) (d)
(e) (f)
Figure 4.9: The effect of varying bandwidth on: (a) normalized Sirius MRI marker signal, (b)
normalized image noise, (c) normalized Sirius MRI marker signal-to-noise ratio (SNR), (d)
contrast-to-noise ratio (CNR) between the Sirius MRI marker and the prostate in phantom,
(e) echo time TE and repetition time TR, (e) scan times. Adapted from T. Y. Lim, R. J.
Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank.
“Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI
markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
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Figure 4.10: Shift artifact. At narrower bandwidths, the marker shift in the frequency-
encoding direction due to the chemical shift artifact is greater. Reprinted from T. Y. Lim,
R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J.
Frank. “Effect of pulse sequence parameter selection on signal strength in positive-contrast
MRI markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
122.07 Hz/pixel ≤ BW ≤ 433.98 Hz/pixel (Figure 4.9f).
Artifacts At very narrow BW, I observed reduced seed susceptibility artifact and promi-
nent shift of the Sirius MRI marker in the frequency-encoding direction, potentially due
to a chemical shift artifact§ (Figure 4.8 and Figure 4.10). At narrower BW, the shift
artifact observed in the frequency-encoding direction was greater (Figure 4.8). For BW ≥
122.07 Hz/pixel, the mean marker shifts were < 1 mm; for BW ≥ 325.51 Hz/pixel, the mean
shifts of the Sirius MRI markers were < 0.2 mm (Figure 4.10). At wider BW, Sirius MRI
marker chemical shift and seed susceptibility artifacts were reduced. The impact of the Sirius
MRI markers’ shift artifact on dosimetry depends on the seed localization method. The shift
extent must be accounted for if the marker locations are used to extrapolate to the seed
locations. On the other hand, the shift artifact would be less consequential if the markers
were simply used to confirm that the negative-contrast voids adjacent to positive-contrast
markers are seeds (for instance, during manual seed localization). Furthermore, although
the Sirius MRI marker shift is distinct on phantom images, it may be difficult to distinguish
§The chemical shift artifact arises when a compound’s protons resonates at a slightly higher or lower
frequency than is expected of water protons at the same location. Since spatial information on MRI images is
encoded based on frequencies, the different frequency emitted by the compound’s protons result in a location
offset.
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the Sirius MRI marker if its signal is shifted into the prostatic stroma.
At narrower BW, there was less noise and higher SNR, while at wider BW, there was less
susceptibility artifacts and chemical shift artifacts.102 For the highest SNR with scan time
< 10 minutes and mean marker shift < 0.2 mm, I recommend using BW = 325.51 Hz/pixel
(±83.33 kHz).
4.4.4 Varying Field-of-view
At smaller FOV, the Sirius MRI marker is more distinctive (Figure 4.11). In the following,
the effect of FOV on several image quality considerations for post-implant dosimetry purposes
is illustrated.
Signal Smaller FOV was associated with increased signal (Figure 4.12a) due to the longer
TR and partial volume artifact. As FOV decreases, the BW (the signal sampling rate)
decreases (Equation 4.2), hence the signal sampling time increases, resulting in longer TR
(Figure 4.12e), contributing to higher signal, but also longer scan times (Figure 4.12f).
Noise Smaller FOV was associated with increased noise (Figure 4.12b).
Signal-to-noise ratio SNR was slightly higher at smaller FOV (Figure 4.12c).
Figure 4.11: The effect of varying field of view on the visual appearance of images. Reprinted
from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao,
G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal strength
in positive-contrast MRI markers for MRI-based prostate post-implant assessment”. In:
Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists in
Medicine).
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(e) (f)
Figure 4.12: The effect of varying field-of-view on: (a) normalized Sirius MRI marker
signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise ratio
(SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the prostate
in phantom, (e) echo time TE and repetition time TR, (e) scan times. The dotted vertical
lines denote the FOV giving the active cross-sectional area of the Sirius MRI markers; hence
the acquisition pixel sizes of points to the left of the dotted line were less than the marker’s
active cross-sectional and were least subjected to partial volume averaging artifacts. Adapted
from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao,
G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal strength
in positive-contrast MRI markers for MRI-based prostate post-implant assessment”. In:
Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists in
Medicine).
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Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.9d).
Timing At smaller FOV, the TR and scan times are longer (Figure 4.12f).
Resolution At smaller FOV, in-plane resolution was better and the markers were more
conspicuous (Figure 4.13).
Artifacts The use of a small FOV corresponded to small voxel sizes. Theoretically, smaller
voxel sizes have less spins in the voxel resulting in lower signal. However, I observed higher
signal (Figure 4.12a) and SNR (Figure 4.12c) at smaller FOV. This is most likely due to the
small size of the markers causing the partial volume averaging artifact to dominate, whereby
higher resolution images allow partial volume objects that are smaller than the voxel size
to be visible102 (see Figure 4.13 for the resolution at varying FOV.) Smaller voxels were
more likely to contain signal from the marker only, resulting in higher signal; larger voxels
succumbed to the partial volume averaging artifact whereby marker and non-marker signals
were averaged out, resulting in lower signal (Figure 4.12a) and lower visibility of the marker
(Figure 4.11). The acquisition pixel sizes using FOV = 10 cm and FOV = 12 cm were less
than the marker’s active cross-sectional area (left of dotted line in Figure 4.12a), and thus
may be least subjected to the partial volume artifact. Smaller FOV resulted in less partial
volume artifact, but was more susceptible to the aliasing/wraparound artifact observed in
the phase-encoding direction (Figure 4.14). Phase-oversampling only oversamples one-half of
the FOV at each end in the phase-encoding direction, hence signals outside these limits may
still wrap into the FOV. To prevent the wrap artifact, larger FOV could be used. However,
if a smaller FOV is desired, the use of an endorectal coil may render the wrap artifact less
prominent by conforming signal reception in a smaller area.
At smaller FOV, the scan time is longer and the wrap artifact is more prominent; at larger
FOV, the partial volume averaging artifact may impair accurate marker localization. For
scan times < 10 min, I recommend a mid-range FOV of 14 cm to 16 cm.
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Figure 4.13: The effect of varying field-of-view on acquisition pixel size. The smaller the
pixel size, the greater the image spatial resolution. The dotted horizontal line denotes the
markers active cross-sectional area; hence points above the dotted line are subjected to
partial volume artifacts.
Figure 4.14: Images acquired at varying field-of-view (FOV) values and the associated wrap
artifact in the phase-encoding direction. Note that the wrap artifact is more severe at smaller
FOVs. The image set acquired with FOV = 8 cm were excluded from SNR measurements
because of the severe wrap artifact.
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4.4.5 Varying Slice Thickness
The images appeared noisier at thinner ∆z but the Sirius MRI markers cannot be reliably
localized at thicker ∆z (Figure 4.15). In the following, the effect of ∆z on several image
quality considerations for post-implant dosimetry purposes is illustrated.
Signal Using smaller ∆z, the signal was higher (Figure 4.16a).
Noise The noise was higher at smaller ∆z (Figure 4.16b).
Signal-to-noise ratio Therefore, over varying effective ∆z ≤ 1.5 mm (reconstructed
marker’s active length), there was no significant change in SNR (slope = -0.0376, p = 0.2707)
(Figure 4.16c).
Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.16d).
Timing Using thin slices did not affect TE and TR, but to cover the same volume, more
slices and longer scan times were needed (Figure 4.16f).
Resolution At smaller ∆z, the through-plane resolution is better and the ends of the
Sirius MRI maker can be better visualized (Figure 4.15).
Artifacts At larger ∆z, the partial volume averaging artifact was more severe (Figure
4.15 and 4.18). Images with effective ∆z = 1.5 mm were interpolated from images acquired
with input ∆z = 3.0 mm, which is the filled length of the marker. This may be why there
was no significant change in the SNR for varying effective ∆z ≤ 1.5 mm (Figure 4.16c), but
the SNR for effective ∆z > 1.5 mm were statistically significantly lower due to the partial
volume averaging artifact. At smaller ∆z, the same marker could be seen traversing across
more slices and appeared brighter because the voxels with marker contain mostly signal from
the marker. At very thin ∆z (effective ∆z < 0.7 mm), the through-plane resolution was
improved, but much longer scan time was required to cover the same volume (Figure 4.16f)
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and miniscule bubbles in the marker may cause a disjointed artifact that can potentially
confound accurate marker localization. Conversely, very thick ∆z resulted in the inability
to discern marker versus seed due to low through-plane resolution. Extreme partial volume
averaging artifact was observed for effective ∆z > 2.5 mm, hence I did not report on the
signal, noise, or SNR of the marker on those images. In fact, on most slices of the scan
acquired with ∆z = 5.0 mm, all the needle tracks contained a hyperintense signal (Figure
4.18). This is because each needle track contained a seed-marker strand, where the marker
signal overwhelmed the voxels. Figure 4.17 illustrates the marker appearance across axial
slices for varying ∆z¶.
To minimize the disjointed artifact, partial volume averaging artifact and for scan time < 10
minutes, I recommend effective ∆z of 0.7 mm to 1.5 mm. Adequately thin image slices may
allow us to obtain the orientation of the marker. Orientation information from the marker
can be coupled with the seed’s dumbbell artifact to estimate the seed’s orientation, such
that treatment planning systems may incorporate seed anisotropy calculations to generate
more accurate dose distributions.
4.4.6 Varying Encoding Steps
At lower Nx ×Ny, the Sirius MRI markers cannot be reliably localized (Figure 4.19). In
the following, the effect of Nx ×Ny on several image quality considerations for post-implant
dosimetry purposes is illustrated.
Signal Theoretically, larger voxel sizes are associated with higher SNR, but in the mea-
surements I observed higher SNR using smaller voxel sizes, most likely owing to dominance
¶Looking down the column of effective ∆z = 1.0 mm, the topmost slice showed the hypointense seed void,
followed by slices with the hyperintense markers, ending with the bottommost slice showing the beginning
of the hypointense void of the next seed. However, if the marker was not perfectly filled with the contrast
agent, using very small ∆z would result in a disjointed artifact. On the other hand, looking down the column
of effective ∆z = 0.5 mm, in the middle of the marker there was no hyperintense signal characteristic of
the marker, most likely owing to the presence of a tiny air bubble. For effective ∆z > 0.5 mm, the partial
volume averaging artifact helped reduce the appearance of the bubble, at the expense of lowered signal since
the voxel contained air as well. Hence, at very small ∆z, the through-plane resolution was improved, but
miniscule bubbles in the marker may cause a disjointed artifact. Last but not least, looking down the column
of effective ∆z = 5.0 mm, the hyperintense signal in the middle of the needle track could be seen on both
slices.
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Figure 4.15: The effect of varying slice thickness on the visual appearance of images.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan,
A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal
strength in positive-contrast MRI markers for MRI-based prostate post-implant assessment”.
In: Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists
in Medicine).
of the partial volume averaging artifact. (See Figures 4.21 for the acquisition pixel sizes in
relation to the marker’s active cross-sectional area.)
Noise At higher Nx ×Ny, the signal was higher (Figure 4.20a), but the noise was also
higher (Figure 4.20b).
Signal-to-noise ratio The SNR increased with Nx×Ny, but leveled off beyond 320× 320,
where the acquisition pixel size is smaller than the marker’s active cross-section, which
is associated with minimal partial volume averaging artifacts (Figure 4.20c). For images
acquired with encoding steps ≥ 320× 320, there was no statistically significant difference in
SNR (Figure 4.20c).
Contrast-to noise-ratio The trend of the CNR between Sirius MRI marker and “prostate”
is similar to the trend of SNR for Sirius MRI markers because the signal of the Sirius MRI
marker is much greater than the signal of the “prostate” (Figure 4.20d).
Timing With higher Nx×Ny, scan time was longer (Figure 4.20f). The zero filling process‖
can be used to reduce scanning time without too much SNR loss. Higher Nx ×Ny required
longer TR, and scan time increased proportionally (Figure 4.20f).
‖Zero filling was used to allow for lower acquisition resolution but increased apparent displayed resolution.
Since extra zeroes contain no signal or noise, zero filling should not affect SNR.
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(a) (b)
(c) (d)
(e) (f)
Figure 4.16: The effect of varying slice thickness on: (a) normalized Sirius MRI marker
signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise ratio
(SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the prostate
in phantom, (e) echo time TE and repetition time TR, (e) scan times. The dotted vertical
lines denotes the markers reconstructed active length; hence the points to the right of the
line are subjected to more partial volume averaging artifacts. Adapted from T. Y. Lim,
R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J.
Frank. “Effect of pulse sequence parameter selection on signal strength in positive-contrast
MRI markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
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Figure 4.17: The appearance of a single marker across consecutive axial slices (vertical) for
images acquired with varying slice thicknesses, ∆z (horizontal). The displayed images are
arranged as axially-linked to the axial slices of the first column, that is, scrolling through the
12 axial slice images shown in the column of effective ∆z = 0.5 mm is equivalent in location
to scrolling through the 3 axial slice images of the column of effective ∆z = 2.0 mm. The
dotted vertical line denotes the markers reconstructed active length.
Figure 4.18: On most slices of the scan acquired with ∆z = 5.0 mm, all the needle tracks
contained a hyperintense signal.
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Figure 4.19: The effect of varying encoding steps on the visual appearance of images.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan,
A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal
strength in positive-contrast MRI markers for MRI-based prostate post-implant assessment”.
In: Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists
in Medicine).
Resolution The in-plane resolution is better with higher Nx ×Ny (Figure 4.21).
Artifacts At lower Nx ×Ny, the partial volume averaging artifact was more prominent as
a single voxel was more likely to contain signals from disparate objects, such as the Sirius
MRI marker, needle track and “prostate”.
For the highest in-plane resolution with scan time < 10 minutes, I recommend a square
256× 256 acquisition matrix (interpolated to 512× 512). To examine the effect of varying
Nx ×Ny on signal, noise and SNR, I examined the effects of varying Nx and Ny separately.
4.4.6.1 Varying Frequency Encoding Steps
Increasing Nx increased the signal (Figure 4.23a), but the noise increased as well (Figure
4.23b). SNR increased with increasing Nx, but leveled off beyond 320× 320, where the
acquisition pixel size was smaller than the marker’s active cross-section and the partial
volume artifact was minimal (Figure 4.23c). The trends of signal, noise and SNR were
inferred from examining the trends of varying Ny only and varying Nx × Ny. Scan time
increased proportionally with increasing Nx (Figure 4.23f). Since the frequency-encoding
gradient is on during echo sampling, increasing the number of Nx (while keeping BW and
sampling interval constant) increases the sampling time, thereby increasing TE, TR and
scan time (Figure 4.23f). The markers were still visible at low Nx, but image resolution was
poor (Figure 4.22). Although scan time can be shortened by lowering Nx (Figure 4.23f),
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(a) (b)
(c) (d)
(e) (f)
Figure 4.20: The effect of varying encoding steps on: (a) normalized Sirius MRI marker
signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise ratio
(SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the prostate
in phantom, (e) echo time TE and repetition time TR, (e) scan times. The dotted vertical
line denotes the encoding steps resulting in an acquisition pixel size corresponding to the
active cross-sectional area of the Sirius MRI markers; hence points to the left of the line are
subjected to partial volume averaging artifacts. Adapted from T. Y. Lim, R. J. Kudchadker,
J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank. “Effect of
pulse sequence parameter selection on signal strength in positive-contrast MRI markers for
MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96 (with permission
from the American Association of Physicists in Medicine).
94
Chapter 4 Pulse Sequence Parameter Variations in Phantom
Figure 4.21: The effect of varying encoding steps on acquisition pixel size. The smaller the
pixel size, the greater the image spatial resolution. The dotted horizontal line denotes the
active cross-sectional area of the Sirius MRI markers; hence points above the dotted line are
subjected to partial volume averaging artifacts.
Figure 4.22: The effect of varying frequency encoding steps on the visual appearance of
images. Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J.
MacLellan, A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection
on signal strength in positive-contrast MRI markers for MRI-based prostate post-implant
assessment”. In: Med Phys 43.7 (2016)96 (with permission from the American Association
of Physicists in Medicine).
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(a) (b)
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Figure 4.23: The effect of varying frequency encoding steps on: (a) normalized Sirius MRI
marker signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise
ratio (SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the
prostate in phantom, (e) echo time TE and repetition time TR, (e) scan times. The dotted
vertical line denotes the encoding steps resulting in an acquisition pixel size corresponding
to the active cross-sectional area of the Sirius MRI markers; hence points to the left of the
line are subjected to partial volume averaging artifacts. Adapted from T. Y. Lim, R. J.
Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank.
“Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI
markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
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Figure 4.24: The effect of varying phase encoding steps on the visual appearance of images.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan,
A. Rao, G. Ibbott, and S. J. Frank. “Effect of pulse sequence parameter selection on signal
strength in positive-contrast MRI markers for MRI-based prostate post-implant assessment”.
In: Med Phys 43.7 (2016)96 (with permission from the American Association of Physicists
in Medicine).
SNR (Figure 8b) and in-plane resolution (Figure 4.22) would be reduced due to partial
volume averaging effects.
4.4.6.2 Varying Phase Encoding Steps
Increasing Ny increased the signal proportionally (Figure 4.25a) and increased the noise by√
Ny (Figure 4.25b), resulting in a net
√
Ny increase in SNR (Figure 4.25c), at the expense of
proportional increase in scan time (Figure 4.25f). Theoretically,100 increasing Ny decreases
the voxel size thus decreasing the SNR by 1/
√
Ny. However, from the measurements,
increasing Ny resulted in an increase in SNR by
√
Ny (Figure 4.25c). I postulate that the
trends in signal, noise and SNR observed for varying Ny were heavily determined by the
partial volume averaging artifact, whereby smaller voxel sizes contain a greater percentage
of marker signals. For the measurements of varying Ny, all the acquisition pixel sizes
were greater than the marker’s active cross-sectional area; hence all these measurements
were subjected to partial volume averaging artifacts. The 256× 256 acquisition matrix
yielded acquisition pixel size similar to the marker’s active cross-sectional area. The in-plane
resolution at high Ny was better (Figure 4.24). Reducing Ny is a common technique to
reduce scan time (Figure 4.25f). Although lower Ny shortened scan time (Figure 4.25f),
SNR (Figure 4.25c) and in-plane resolution (Figure 4.24) were reduced due to partial volume
averaging artifacts.
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(a) (b)
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Figure 4.25: The effect of varying phase encoding steps on: (a) normalized Sirius MRI
marker signal, (b) normalized image noise, (c) normalized Sirius MRI marker signal-to-noise
ratio (SNR), (d) contrast-to-noise ratio (CNR) between the Sirius MRI marker and the
prostate in phantom, (e) echo time TE and repetition time TR, (e) scan times. The dotted
vertical line denotes the encoding steps resulting in an acquisition pixel size corresponding
to the active cross-sectional area of the Sirius MRI markers; hence points to the left of the
line are subjected to partial volume averaging artifacts. Adapted from T. Y. Lim, R. J.
Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and S. J. Frank.
“Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI
markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7 (2016)96
(with permission from the American Association of Physicists in Medicine).
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Table 4.2: Recommended scan parameters for high visualization of MRI markers, accounting
for scan time, in-plane and through-plane resolution, and artifacts. Reprinted from T. Y.
Lim, R. J. Kudchadker, J. Wang, R. J. Stafford, C. J. MacLellan, A. Rao, G. Ibbott, and
S. J. Frank. “Effect of pulse sequence parameter selection on signal strength in positive-
contrast MRI markers for MRI-based prostate post-implant assessment”. In: Med Phys 43.7
(2016)96 (with permission from the American Association of Physicists in Medicine).
Scan Parameters Values
α 12◦ to 20◦
NEX 2 to 10 (halved due to phase oversampling)
BW ±83.33 kHz
FOV 14 cm to 16 cm
∆z 1.4 mm to 3.0 mm (interpolated to 0.7 mm to 1.5 mm)
Nx ×Ny 256× 256 (interpolated to 512× 512)
4.5 Conclusion
4.5.1 Summary
In this study, the impact of varying scan parameters on marker visualization were presented,
and the scan parameters that led to best marker visualization were defined. From the range
of investigated values, the highest MRI marker SNR were independently given by α = 12◦,
NEX = 25 (scan time = 22.9 minutes), BW = ±19.23 kHz (shift = 1.42± 0.37 mm), FOV =
12 cm and 384× 384. However, the scan parameters that provided the highest MRI marker
SNR may not be the best choice from a practical standpoint. Taking into consideration SNR,
scan time, resolution and artifacts, the recommended scan parameters based on this phantom
study are listed in Table 4.2. This phantom study provides a practical understanding on
the impact of pulse sequence parameter adjustments on marker visibility, image quality,
and scan time, thus allowing for a more directed effort to be made for marker evaluation in
patients.
4.5.2 Limitations
The main limitation of this study is that not every possible combination of all the scan
parameters was covered because it would be extremely laborious to acquire images and
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perform analysis for all possible scan parameter combinations∗∗. Nevertheless, I presented
all signal, noise and SNR values normalized to that acquired using baseline scan parameters
(bold font in Table 4.1), so that different plots can be studied together to estimate gains/losses
in signal, noise, and SNR for the desired combination of scan parameters. However, this
estimation needs to account for the interactions between the pulse sequence parameters.
Another limitation of the study is that the metric used was signal instead of contrast,
because this study is a phantom study, but contrast is dependent on the prostate and other
tissues in the imaging volume. Measuring true contrast between marker and prostate is
problematic due to inter-patient variation, intra-patient variation, scan time, and ethical
considerations. Inter-patient variation owing to differences in prostate T1 and T2 from
patient to patient compels all measurements to be done in a single patient to be able to
isolate the effect of scan parameter variation from inter-patient variation. However, there
is also intra-patient variation, because different prostate zones exhibit different contrast
and the presence of edema enhances regions within the prostate, resulting in the contrast
measurements being affected by the marker position within the prostate. Statistics aside,
looking at only a single marker in a specified location within the prostate for a single patient,
the total continuous scan time of more than 11 hours would raise patient discomfort, motion,
and tissue heating concerns. The systematic evaluation of the effects on MRI marker signal
for 70 different scan parameter combinations in this phantom study guided the next chapter’s
in-vivo studies of the MRI marker visibility.
The scan parameter values affect the actual TE and TR used on the GE scanner used
for this study. For instance, when changing only the BW at the scanner console in normal
scanning mode, any change in signal was not due solely to the change of BW because the TE
and TR changed as well (Figure 4.9f), thus confounding direct prediction of signal behavior
from equations and necessitating actual measurement of the signal, as was done in this study.
On other scanner manufacturer platforms, the TE and TR may be better controlled even in
clinical mode.
Moreover, the phantom images of the Sirius MRI markers were acquired at room
∗∗From just the discrete number of values for each of the 6 scan parameters studied, there are
12× 13× 11× 7× 13× 15 = 2 342 340 possible combinations.
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temperature, but the indication for the Sirius MRI markers is for implantation into the
human body. However, since at body temperature the T2 is longer, I expect that the Sirius
MRI marker signal would be higher in patient studies compared to this phantom study.
4.5.3 Implications
I have evaluated the effects of α, NEX, BW, FOV, ∆z and Nx ×Ny on Sirius MRI marker
SNR, scan time, resolution and artifacts in a prostate brachytherapy phantom on a GE 3.0
T scanner. The findings of this study may be used to guide MRI protocol development for
high marker visibility to obtain useful post-implant dosimetry images in patients. In the
next chapter, I investigate the visibility of Sirius MRI markers on patient images generated
from various pulse sequences, specifically the 3D FSPGR sequence.
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5.1 Background
Post-implant quality assessment is important to ensure that the radiation dose distribution
from the brachytherapy seeds adequately covers the prostate and is acceptable in nearby
critical structures. Implant quality can be represented by DVH parameters, which correlate
with biochemical control.30,35 For the calculation of DVH parameters, 2 vital pieces of
information are needed: dose information from the seed locations, and volume information
using the boundaries of the prostate and surrounding critical structures. Seed localization
and anatomical delineation are dependent on the post-implant imaging modality.
5.1.1 CT-only post-implant dosimetry
5.1.1.1 Advantages
Consistent seed localization The main advantage of CT-only post-implant dosimetry
is consistent seed localization due to the high visibility of the seeds.27,49,71 In a CT- and
MRI-compatible-phantom study, De Brabandere et al.49 found smaller mean seed localization
errors on CT images (0.9± 0.6 mm) compared to MRI images acquired using FSE sequences
on Philips (2.1± 1.4 mm) and Siemens 1.5 T (2.3± 0.8 mm). In a subsequent patient study,
De Brabandere et al.27 reported the impact of seed localization variability on the standard
deviation of D90 to be 2% for CT-based seed localization, compared to 7% for MRI-based
seed localization. In a separate study, De Brabandere et al.71 further reported D90 variability
of 1.5% using CT compared to 6.6% using MRI-based seed localization.
Time savings CT scans generally takes less time compared to MRI scans, because the
weak MRI signal can be hidden by electronic noise, requiring repetition for each projection.104
A non-contrast CT scan takes approximately 5 to 10 minutes, while a non-contrast MRI
scan takes approximately 30 minutes.
Cost savings The cost for a CT scan is usually less than the cost for an MRI scan.
According to the Healthcare Blue Book,105 a pelvic CT costs $634 while a pelvic MRI costs
$1209.
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(a) Base (b) Mid-gland (c) Apex
Figure 5.1: Superimposed contours on CT images generated by 15 physicians experienced
in brachytherapy and prostate contouring during a workshop aimed at examining prostate
contouring variability. Reprinted from J. Crook, N. Patil, C. Ma, M. McLean, and J.
Borg. “Magnetic resonance imaging-defined treatment margins in iodine-125 prostate
brachytherapy”. In: Int J Radiat Oncol Biol Phys 77.4 (2010), pp. 1079–8431 (license
number: 3876100661790).
5.1.1.2 Disadvantages
Poor soft tissue contrast The main disadvantage of using CT images for post-implant
dosimetry are poor soft tissue contrast and seed streak artifacts, leading to compromised
anatomical contours.
Low precision of prostate contours Prostate delineation on CT is associated with
low precision of prostate contours, that is, high interobserver variability.27,31,43,50 Figure
5.1 depicts the variability in prostate contouring by 15 experienced physicians. Crook et
al.43 found that contours and DVH parameters were not reproducible due to interobserver
variation in prostate contouring. De Brabandere et al.27 found that the standard deviation of
prostate delineation by eight physicians was 23% using CT images, compared to 17% using
MRI images. Dubois et al.44 reported significant interobserver and intraobserver differences
of prostate volumes derived using CT images (insignificant differences using MRI images).
Han et al.25 reported interobserver variability (standard deviation) in prostate volumes
delineated on CT images to range from 9% to 29%, resulting in inadequate implants for 14%
of the implants judged by V100 and 24% judged by D90. In a study of CT-based post-implant
dosimetry at 28 Japanese institutions, Aoki et al50 found significant interobserver variability
in prostate volume and subsequent D90.
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Low accuracy of prostate contours Prostate delineation on CT is also associated
with low accuracy of prostate contours, as prostate volumes can be overestimated on CT
images.51,53,54,59 Petrik et al.59 reported that in their study cohort of 75 patients, the
mean prostate volume was 38.3 cc on CT images compared to 33.3 cc on MRI images.
Normal tissue being incorrectly contoured as part of the prostate on CT images may
delay necessary corrective therapy (implantation of additional seeds) or cause unnecessary
treatment complications.
Low accuracy and precision of normal tissue contours Delineation of the critical
structures near the prostate is challenging, thus limiting management of acute or late
radiation effects as the radiation dose to these critical structures cannot be determined.
High variability in DVH parameter reporting Due to the variability in anatomical
contours, the resultant DVH parameters have high variability,27 thereby obscuring dose-
response relationships.43
5.1.2 CT-MRI Fusion-based Post-implant Dosimetry
5.1.2.1 Advantages
Simultaneous consistent seed localization and excellent anatomical visualization
Amdur et al.106 first proposed CT-MRI fusion to capitalize on seed visualization on CT
images, while still benefiting from soft tissue delineation on MRI scans. On CT-MRI fusion
images (Figure 5.2), seed localization is performed on the hyperintense seeds visible on CT
images.
5.1.2.2 Disadvantages
Registration technique uncertainties The uncertainties during registration affects the
precision and accuracy of CT-MRI fusion. Registration technique variation include differences
in registration landmarks. The landmarks used to guide fusion of the CT and MRI images
include the urethra,106 bladder106 and bones in the pelvis.53 Amdur et al.106 performed
registration using the urethra and base of bladder, and reported average maximum differences
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Figure 5.2: Fused MRI-CT scan of the prostate. Grayscale image, CT scan; red color-washed
image, MRI scan. The MRI scan (3D FSPGR) was acquired with an endorectal coil but the
CT scan was acquired with no rectal distortion, and may lead to misregistration between
the MRI and CT scans.
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of the urethra of 2.5± 0.9 mm. Using bony landmarks, such as pubic arch and femur, to
perform image fusion is sensitive to the impact of bladder and rectal filling. Bony landmarks
stay stationary even when the prostate location gets shifted due to bladder and rectal filling.
The fusion process lends itself to large interobserver variability as small inaccuracies in fusion
results in a displacement of the seed cloud with respect to the prostate, leading to substantial
uncertainty in DVH parameter evaluation.27 Another registration technique variation is
the fusion method,107,108 fusion algorithm parameters and fusion software: CT-MRI fusion
has been be done in the Pinnacle TPS (Philips Radiation Oncology Systems, Fitchburg,
WI)106 and the MIM Symphony TPS.79 Fusion of CT and T2-weighted images can be more
precisely performed using T1-weighted images as an intermediate dataset.
27 De Branbandere
et al.27 reported a large impact of fusion uncertainties on D90 (16%) from the direct fusion
of CT and T2-weighted images, compared to the indirect fusion with T1-weighted images as
an intermediate step (7%). Another variation of registration technique is the variation in
personnel training and experience. Optimal CT-MRI fusion can be time-consuming, and
training of the radiation oncologist, dosimetrist, and/or physicist to identify the relevant
anatomical landmarks is required.
Input uncertainties The precision and accuracy of CT-MRI fusion-based post-implant
dosimetry depends on the CT and MRI image acquisitions. Variation in the quality of
the input data includes differences in pulse sequence and scan parameters (such as slice
thickness27). Various pulse sequences27,74 have been described to allow for fusion with CT
images. Another variation is due to physician experience with contouring. Crook et al.43
found significant differences between the contours made by experienced physicians versus
inexperienced ones, resulting in differences in prostate V100 and D90. Other variations
in the quality of input data are administered contrast, pelvic tilt, prostate edema, seed
orientations, coil types,109 patient travel between CT and MRI scanners, time lapse between
CT and MRI scans, as well as bladder and rectal filling differences on CT and MRI images.
Time and cost Compared to CT-only or MRI-only approaches, the CT-MRI fusion-based
approach incurs extra workload and cost due to the addition of another imaging modality.71
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5.1.3 MRI-only Post-implant Dosimetry
5.1.3.1 Advantages
Excellent soft tissue contrast The positive implications of MRI-only post-implant
dosimetry include superior visualization of anatomy. Bloch et al.67 reported periprostatic
seed enumeration and localization not possible using CT images at the neurovascular bundle,
seminal vesicles, periurethral, penile bulb, Denonvillier’s Fascia/rectal wall and uinary
bladder.
High precision of prostate contours Prostate delineation on MRI is associated with
less interobserver contouring variability compared to CT.27,44,51,52 De Brabandere et al.27
found that although the standard deviation of prostate contours by eight physicians was
lower on MRI images compared to CT images, it was still surprisingly large due to variations
in inclusion of cranial aspects of the gland and margin generosity, thereby calling into
question the increased accuracy of prostate contours on MRI images.
High precision and accuracy of normal tissue contours Consistent quantitation
of dose to critical structures, such as the urinary sphincter,56 would improve evaluation
of dose-response relationships. Buch et al.55 reported that MRI promotes a meaningful
dosimetric assessment of normal tissue that is not possible using CT, for critical structures
such as the urethra, anterior rectal wall, neurovascular bundles and penile bulb.
No ionizing radiation Using the MRI-only post-implant dosimetry approach, no unnec-
essary dose of ionizing radiation is given, unlike with CT.
Imaging flexibility Multiple contrast types can be obtained to illuminate structural and
functional information. For instance, Gillan et al.5 reported DVH evaluation to the internal
pudendal arteries using time-of-flight MR angiography. Apart from using Sirius MRI markers
for MRI-only post-implant dosimetry, other solutions to enable MRI-only have focused on
changing the pulse sequence used for post-implant dosimetry.
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Time and cost savings Compared to CT-MRI fusion-based post-implant dosimetry,
MRI-only post-implant dosimetry saves the time and cost of having to acquire a CT scan.
5.1.3.2 Disadvantages
Seed localization difficulties On MRI images, the brachytherapy seed appear as a
negative void that are larger than the seed’s physical length, and the interpretation of void’s
centroid is subjected to observer interpretation.27 De Brabandere et al.71 found a mean
interobserver variability in MRI-based seed localization (using T1-weighted gradient echo
images) of 3 mm compared to 1.1 mm in CT-based seed localization. The variability in seed
localization on MRI images lead to greater variability in DVH parameters compared to
CT.27,71 However, evaluation of seed localization using DVH parameters only with no spatial
information may obscure poor seed localization.71
Imaging uncertainties The accuracy of prostate and normal tissue contours depends
on the MRI imaging technique. If endorectal coils are used, the inflation may significantly
distort prostate anatomy (Figure 5.3). Also, a limitation of the other potential solutions
to MRI-only post-implant dosimetry is that they were phantom studies and their utility in
patients have yet to be investigated.
Time and cost Compared to CT-only post-implant dosimetry, MRI-only post-implant
dosimetry takes longer and costs more than CT scans, as mentioned in Section 5.1.1.1.
Logistics MRI-based post-implant dosimetry may be subjected to limited availability
of the MRI scanner to the prostate implant team.110 Access to an MRI scanner may
be limited due to scheduling difficulties, the MRI scanner being in a different building or
belonging to a completely different institution. These logistics difficulties increases scheduling
inconveniences to the brachytherapy team and patients themselves.
Complexity MRI is a complex technology and is challenging to learn. Personnel education
is a potential barrier to the adoption of MRI for post-implant dosimetry.
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Figure 5.3: T2-weighted axial and sagittal images from a patient demonstrate the significant
anatomic distortion caused by introduction of an endorectal coil (red dotted line on the
sagittal image highlights the prostate shape). Reprinted from J. M. Albert, D. A. Swanson,
T. J. Pugh, M. Zhang, T. L. Bruno, R. J. Kudchadker, and S. J. Frank. “Magnetic
resonance imaging-based treatment planning for prostate brachytherapy”. In: Brachytherapy
12.1 (2013), pp. 30–761 (licensed under a Creative Commons Attribution-NonCommercial-No
Derivatives License).
5.1.4 Alternatives Solutions (instead of using Sirius MRI Markers) to-
wards MRI-only Post-implant Dosimetry
Using encapsulated contrast agent markers∗ is one of the potential solutions to enable
MRI-only post-implant dosimetry. Dubois et al.70 and Moerland et al.69 were the first
groups to describe seed localization on MRI images. Dubois et al.70 described using a
proton-density-weighted fast spin echo (FSE) sequence to visualize the prostate and localize
seeds, but lamented the steep learning curve in distinguishing seeds from blood vessels
and identification of extraprostatic seeds. Dubois et al.70 acquired the images on a GE
1.5 T Signa MRI scanner with the pulse sequence: “TR — 3000 ms, effective TE — 27 ms;
256× 256 matrix, NEX of 2; 8 kHz bandwidth; 3 mm slice thickness, interleaved, 16 cm FOV,
anterior-posterior phase direction, superior saturation band, flow compensation and no phase
wrap... performed in a pelvic coil and required no more than 15 min to complete.”
Moerland et al.69 used T1-weighted spin echo images for seed localization, but reported
seed placement inaccuracies when the seeds cluster together. McLaughlin et al.54 found that
T2-weighted images are better than T1-weighted images for prostate delineation. However,
∗See Section 1.7 for previous description of the Sirius MRI markers.
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McLaughlin et al.54 concluded that they could not determine an MRI technique that can
reliably identify seeds to allow for MRI-only post-implant dosimetry. Tanaka et al.111 used a
contrast enhanced T1-weighted sequence, which yielded more accurate dosimetry compared
to CT-based, but overestimated D90, V100 and V150 compared to the CT-MRI fusion-based
post-implant dosimetry.
Most of the other solutions to enable MRI-only post-implant dosimetry focus on the
seed artifacts for advanced manipulation of the pulse sequence and post-processing. The
seeds have distinct susceptibility patterns depending on their orientations to the main
magnetic field.93,112,113 By taking advantage of the seeds high magnetic susceptibility, recent
efforts in seed visualization on MRI images include: the use of an Inversion-Recovery
with ON-Resonant Water Suppression (IRON) pre-pulse to spectrally-select off-resonant
protons,114 the use of ultrashort-TE sequences to preserve signal before rapid transverse
dephasing,73 the post-processing use of homodyne high-pass filters of various sizes,115,116 the
use of susceptibility gradient mapping using the original resolution (SUMO) by filtering in
k-space,117 the use of a kernel deconvolution algorithm with regularized L1 minimization118
(the dipole kernel119 and a nominal seed kernel120 has been explored), the use of center-out
Radial Sampling with Off-Resonance reception (co-RASOR) that moves the radial signal
pile-up to the seeds center (using multiple acquisitions121 and only a single acquisition122),
and the use of multi-echo gradient recalled echo sequences.123 However, imaging susceptibility
may be inconsistent across MRI slices, difficult to locate accurately, and more challenging in
heterogeneous tissue.116
5.2 Purpose
Sirius MRI markers may allow for the full integration of MRI for post-implant dosimetry by
helping to overcome the barrier of seed localization difficulties on MRI images. Visualization
of the Sirius MRI markers have been well-characterized in phantom (Figure 5.4) as described
in the last chapter, but the feasibility of using these Sirius MRI markers in patients was
unknown at the time of study. This chapter describes the initial patient experience in
developing an appropriate MRI protocol for Sirius MRI marker visualization, and the process
111
Chapter 5 MRI Protocol Development in Patients
(a) Photograph (b) Sagittal MRI (c) Axial MRI
Figure 5.4: (a) Photograph of markers between brachytherapy seeds. (b) The appearance
of markers (hyperintense cylinder) between seeds (hypointense dumbbell-shaped voids) in
a commercially available prostate phantom. The displayed sagittal slice was obtained at
a plane crossing the center of the topmost marker. (c) Axial view in a prostate phantom.
Markers appear definitively as hyperintense regions, whereas signal voids may be seeds
or needle tracks. Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, T. Bathala,
J. Szklaruk, T. J. Pugh, U. Mahmood, G. S. Ibbott, and S. J. Frank. “Development of an
MRI protocol to visualize encapsulated contrast agent markers in prostate brachytherapy
recipients: Initial patient experience”. In: J Contemp Brachytherapy 8.3 (2016)103 (licensed
under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License).
of incorporating the markers into our LDR prostate brachytherapy clinical practice.
5.3 Methods
5.3.1 Sirius MRI Markers in the Prostate Implant Workflow
In an institutional process quality improvement protocol, 10 prostate cancer patients selected
to undergo LDR prostate brachytherapy were evaluated. Various imaging modalities, such as
transrectal ultrasound (TRUS), CT and MRI, were used throughout the implant workflow.
Pre-implant Prior to the implant, TRUS and MRI images were acquired. These pre-
implant images were used to generate the treatment plan on MIM Symphony (MIM,
Cleveland, OH), which was evaluated in Chapter 2. The treatment plan dictated the ordering
of seeds and markers in a unique configuration for each patient. The Sirius MRI markers
(C4 Imaging, Houston, TX) contain cobalt dichloride-N-acetyl cysteine encapsulated in a
polymer capsule of 5.5 mm length, 0.8 mm diameter, and have been approved by the United
States Food and Drug Administration for LDR prostate implants. The seed-marker strands
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were ordered depending on the isotope and seed manufacturer (IsoRay Medical, Richland,
WA; IsoAid, Port Richey, FL; Theragenics, Buford, GA) with appropriate sterilization of
the strands.
Implant The seed-marker strands were implanted in patients under TRUS- and template-
guidance in the same manner as seed-spacer strands.
Post-implant After the implant, CT and MRI scans were acquired on the day-of-implant
and again approximately a month later. The post-implant CT images were used to perform
post-implant dosimetry for all patients according to the current standard of care. The post-
implant MRI images were evaluated for marker, seed and prostatic anatomy visibility, as well
as artifacts, including marker chemical shift, partial volume averaging, seed susceptibility,
motion, and wraparound artifacts.
5.3.2 Post-implant MRI Protocol
Previously, our institution’s post-implant MRI protocol consisted of 3D T2-weighted FSE,
2D T2-weighted FSE (axial), and 2D T1-weighted FSE (axial/sagittal/coronal) sequences.
The 3D T2-weighted FSE sequence (GE: CUBE; Siemens: SPACE, Sampling Perfection with
Application optimized Contrasts using different flip angle Evolution) was routinely used for
fusion with CT images.
The updated post-implant MRI protocol consists of a 3D fast radiofrequency-spoiled
gradient-recalled echo (FSPGR) sequence, with the scan parameters defined based on the
phantom studies described in Chapter 4 and repeat 3D FSPGR scans performed to optimize
the sequence for post-implant dosimetry (Table 5.1).
MRI scans were acquired using a Signa HDxt 3.0 T scanner (GE, Waukesha, WI) for
eight patients, a Signa HDxt 1.5 T scanner (GE, Waukesha, WI) for one patient, and a
MAGNETOM Aera 1.5 T scanner (Siemens, Malvern, PA) with the similar fast low angle
shot (FLASH) sequence for one patient. Except for the first patient, all patients were imaged
with a disposable inflatable endorectal coil (Medrad R©; Bayer, Whippany, NJ). Surface
Coil Intensity Correction (SCIC) and Phased array UnifoRmity Enhancement (PURE)
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Table 5.1: Pulse sequences for post-implant dosimetry. Reprinted from T. Y.
Lim, R. J. Kudchadker, J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh, U.
Mahmood, G. S. Ibbott, and S. J. Frank. “Development of an MRI protocol to
visualize encapsulated contrast agent markers in prostate brachytherapy recipi-
ents: Initial patient experience”. In: J Contemp Brachytherapy 8.3 (2016)103
(licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License).
3D T2W FSE 3D FSPGR
Scanner manufacturer GE GE GE Siemens
Field strength (T) 3.0 3.0 1.5 1.5
Scan plane Axial Axial Axial Axial
TR/TE (ms) 2000/120 8/2 8/3.6 12/2.4
FOV (cm) a 14 14 16 14
BW (Hz/pixel) 122 326 244 500
Echo train length 74 - - -
θ (◦) - 20 25 25
∆z (mm) 1 1 b 1 b 1 b
Matrix size c 512× 512 512× 512 512× 512 512× 512
NEX 1 4 4.5 2
Frequency direction R/L A/P A/P A/P
a Square field-of-view
b Interpolated from 2 mm
c Interpolated from 256× 256
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Figure 5.5: Axial (a), sagittal (b) and coronal (c) views of the prostate acquired using
CT. Markers could not be visualized. Seeds appeared hyperintense with streak artifacts.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh,
U. Mahmood, G. S. Ibbott, and S. J. Frank. “Development of an MRI protocol to visualize
encapsulated contrast agent markers in prostate brachytherapy recipients: Initial patient
experience”. In: J Contemp Brachytherapy 8.3 (2016)103 (licensed under Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International License).
post-processing were applied to minimize the high signal intensity proximal to the endorectal
coil. All patients were imaged in the supine position.
5.4 Results and Discussion
5.4.1 Visualization of Seeds and Sirius MRI Markers
CT Images On the CT images (Figure 5.5), the markers appeared similar in intensity to
the prostate tissue and were obscured by the seeds. On the other hand, the seeds appeared
as hyperintense cylinders. The seed positions were confounded by the metal streak artifacts
and partial volume averaging artifacts, appearing longer and wider than the seeds’ physical
dimensions.
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Figure 5.6: Axial (a), sagittal (b) and coronal (c) views of the prostate acquired using a
3D FSE sequence. The hypointense seeds and markers were not clearly distinguishable.
Reprinted from T. Y. Lim, R. J. Kudchadker, J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh,
U. Mahmood, G. S. Ibbott, and S. J. Frank. “Development of an MRI protocol to visualize
encapsulated contrast agent markers in prostate brachytherapy recipients: Initial patient
experience”. In: J Contemp Brachytherapy 8.3 (2016)103 (licensed under Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International License).
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Figure 5.7: Axial (a), sagittal (b) and coronal (c) views of the prostate acquired using a
3D FSPGR sequence. Markers appeared as hyperintense cylinders, while seeds appeared
as hypointense dumbbell-shaped susceptibility voids. Reprinted from T. Y. Lim, R. J.
Kudchadker, J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh, U. Mahmood, G. S. Ibbott,
and S. J. Frank. “Development of an MRI protocol to visualize encapsulated contrast agent
markers in prostate brachytherapy recipients: Initial patient experience”. In: J Contemp
Brachytherapy 8.3 (2016)103 (licensed under Creative Commons Attribution-NonCommercial-
ShareAlike 4.0 International License).
FSE Images On the standard post-implant protocol’s 3D T2-weighted FSE images (Figure
5.6), the markers and seeds appeared inconsistently as hypointense cylinders or isointense to
prostatic tissue. Unclear distinction between seeds and markers confounded seed localization.
Prostate anatomy was better visualized on the 3D T2-weighted FSE images. This is consistent
with the consensus MRI experts’ opinion (such as from the European Society of Urogenital
Radiology124) that T2-weighted images yield the best visualization of the prostate zones and
capsule.
FSPGR Images On the updated protocol’s 3D FSPGR images (Figure 5.7), the mark-
ers appeared as hyperintense cylinders within the hypointense needles tracks, giving the
characteristic appearance on axial images of bright filled circles with a dark outline. A
chemical shift artifact of the marker was pronounced at low BW. The marker chemical shift
artifact results from slight differences between the Larmor frequencies of hydrogen spins
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in the marker and the prostate, thereby displacing the marker in the frequency-encoding
direction. The presence and magnitude of this displacement depends on BW and matrix
size. The BW should be high enough for minimal marker displacement but low enough
for acceptable noise. To reduce partial volume averaging artifacts due to the small size of
the markers, I used 0.27 mm× 0.27 mm× 1 mm voxels. The number of averages used was
relatively high compared to standard sequences to increase the signal-to-noise ratio (SNR).
The seeds appeared as hypointense dumbbell-shapes, with wider ends of the seeds
compared to the center. These dumbbell-shaped seed susceptibility artifacts were seen
owing to the higher magnetic permeability of the seeds’ metallic casing, especially at the
end-welding, compared to background prostatic tissue. This causes the magnetic field to
be distorted near the seeds, leading to spatial variation in local tissue relaxation times.102
The seed susceptibility artifact was more pronounced at low BW and more visible on 3D
FSPGR images compared to 3D FSE images due to the lack of a 180 pulse that cancels
out magnetic field inhomogeneity. The seed susceptibility artifact, along with the markers,
enabled easier seed centroid identification.
Intraprostatic detail was not as clearly visualized with the 3D FSPGR sequence (Figure
5.7) as with the 3D T2-weighted FSE sequence (Figure 5.6). The prostate demonstrated a
homogenous signal intensity and the prostatic zones were not easily discernible. Nevertheless,
for post-implant dosimetry purposes, only prostate boundary delineation was needed. Figure
5.8 shows the contouring of relevant structures on the 3D FSPGR sequence images.
5.4.2 Clinical Challenges
Motion artifact Patient motion caused a ripple appearance in the phase-encoding direc-
tion due to improper registration of phase information, which obscured prostate margins
and impaired seed and marker identification (Figure 5.9). The motion artifact could be
expected owing to peristaltic or respiratory motion during the long (>10 minutes) image
acquisition. Similar to diagnostic sequences, these motion artifacts should be directed away
from the prostate by setting the phase-encoding direction to right/left (R/L) (Figure 5.9b).
Motion artifacts can also be minimized by reducing scan time.
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Figure 5.8: Delineation of the contours (prostate, thick blue lines; bladder, thick yellow
lines; rectum, thick green lines) and identification of the radioactive seeds assisted by the
use of positive-contrast MRI markers (thin lines are isodose lines) in a set of 3D-FSPGR
MRI scans (axial, sagittal, and coronal views shown).
(a) Phase-encoding direction = A/P (b) Phase-encoding direction = R/L
Figure 5.9: Impact of motion artifact on axial views of the prostate acquired using a 3D
FSPGR sequence depends on the phase-encoding direction. Reprinted from T. Y. Lim,
R. J. Kudchadker, J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh, U. Mahmood, G. S. Ibbott,
and S. J. Frank. “Development of an MRI protocol to visualize encapsulated contrast agent
markers in prostate brachytherapy recipients: Initial patient experience”. In: J Contemp
Brachytherapy 8.3 (2016)103 (licensed under Creative Commons Attribution-NonCommercial-
ShareAlike 4.0 International License).
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(a) No wrap artifact (b) Wrap artifact
Figure 5.10: Axial views of the prostate acquired using a 3D FSPGR sequence with (a) no
wrap artifact versus (b) with wrap artifact. Reprinted from T. Y. Lim, R. J. Kudchadker,
J. Wang, T. Bathala, J. Szklaruk, T. J. Pugh, U. Mahmood, G. S. Ibbott, and S. J. Frank.
“Development of an MRI protocol to visualize encapsulated contrast agent markers in prostate
brachytherapy recipients: Initial patient experience”. In: J Contemp Brachytherapy 8.3
(2016)103 (licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License).
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Wraparound artifact The wraparound artifact (Figure 5.10b) was seen in the phase-
encoding direction owing to improper assignment of phase-shift information. Depending
on the extent of the wrap artifact, marker visibility could be affected. To reduce this
artifact, a common technique is to set the phase-encoding direction to anterior/posterior
because the anteroposterior width usually has the shortest skin-to-skin distance (Figure
5.11a). However, since the imaging FOV was smaller than the anteroposterior width of most
patients, patient anatomy outside the FOV would wrap into the image. In this study, to
reduce the wraparound artifact, I oversampled the FOV (Figure 5.11b), used saturation
bands to reduce superimposed signal from outside the imaging FOV, and kept the patient’s
arms away from their sides.
Minimizing the motion artifact and wraparound artifact required the phase-encoding
to be set in different directions. Nevertheless, using phase oversampling, the wraparound
artifact would not extend into the prostate; hence preventing the motion artifact from
impinging into the prostate region could be prioritized to ensure visualization of the prostate
boundaries and markers/seeds within the prostate for the purposes of post-implant dosimetric
evaluation. Therefore, the phase-encoding direction should be set to R/L. For patients with
lateral widths greater than the oversampled FOV (Figure 5.12), the wrap artifact would
be observable (hyperintense tissue visible on R/L edges of the axial and coronal views of
Figure 5.7).
Biomedical implants Patients’ biomedical implants may be contraindicated for 3.0 T
MRI, but they may be allowed to be scanned at lower field strengths. A reduction in field
strength corresponds to a reduction in power deposition in the patient, relaxation times,
susceptibility artifact effect, SNR, and geometric distortion. At 1.5 T, the image quality was
reduced compared to 3.0 T images, but the visibility of the markers was not compromised.
Scanner manufacturers Regardless of the MRI scanner manufacturer, consistent and
uniform protocols are essential. The MRI markers could be visualized on both GE and
Siemens scanner platforms. The convenience of using the clinically-available 3D FSPGR
pulse sequence compared to novel pulse sequences for MRI-based post-implant dosimetry
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(a) Without phase oversampling
(b) With phase oversampling
Figure 5.11: Wrap artifact in the phase-encoding = A/P direction.
Figure 5.12: Wrap artifact in the phase-encoding = R/L direction.
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was that the scan parameters could be matched with similar pulse sequences of different
scanner manufacturers.
Coils Endorectal coils are routinely used to enhance the prostate signal for diagnostic
sequences, as the prostate is centered in the body while signal from the torso coil falls off away
from the skin. However, the endorectal coil is not routinely used in the post-implant setting
within the LDR prostate brachytherapy community. Dubois et al.,70 who first presented the
use of MRI for post-implant dosimetry, recommended the pelvic coil and discouraged the use
of the endorectal coil, citing concerns due to distortion of the prostate’s posterior edge, the
signal gradient artifact proximal to the endorectal coil and patient discomfort. Even for the
acquisiton of pre-implant images, Albert et al.61 cautioned against using an endorectal coil
due to anatomical distortion. However, identification of the seeds and markers was impossible
without the endorectal coil (Figure 5.10a). Depending on the size of the endorectal coil, it
may deform the prostate (Figure 5.3), resulting in CT-MRI fusion difficulties and producing
unnatural dose distributions. However, the endorectal coil can provide greater consistency
towards the ultimate goal of an MRI-only LDR prostate brachytherapy workflow. In this
study, to reduce prostate deformation while maintaining coil immobility, the endorectal coil
was slightly inflated to only 30 cc instead of maximum inflation. Proper communication
with the patient regarding the benefit of the endorectal coil was necessary to ensure patient
cooperation.
5.5 Conclusion
5.5.1 Summary
Post-implant dosimetry improves care by allowing for corrective measures to be taken if
necessary, and can improve the care of future patients through implant quality feedback to
the brachytherapy team. Communication of the methodology and end-points of post-implant
dosimetric assessment by the brachytherapy team to the MRI team is crucial to ensure
useful images are acquired while maintaining high SNR, minimal artifacts, and reasonable
scan time.
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This chapter described the development of an MRI protocol for Sirius MRI marker and
prostate visualization, and the incorporation of markers into our LDR prostate brachytherapy
clinical practice. This is the first study presenting the appearance of MRI markers in human
prostate, and the first evaluation of the practical feasibility of using these markers as part of
the LDR prostate brachytherapy workflow. The MRI protocol consists of a 3D FSPGR scan
for marker visualization, and an optional 3D T2-weighted FSE scan for detailed anatomical
visualization. The 3D FSPGR scan may be used as the sole image set to identify markers
and seeds, and provides adequate prostate edge visualization for contouring. However,
CT-MRI fusion can be done using either the 3D FSPGR or 3D FSE scans in our protocol
for fusion with CT images, if desired. Especially on the 3D FSPGR images, the markers can
be visualized, potentially allowing for greater registration to CT images, as the markers and
seeds are interleaved. MRI-MRI fusion post-implant dosimetry can also be straightforwardly
done with our protocol’s 3D FSPGR and 3D FSE scans, as these scans were acquired
consecutively using an endorectal coil with the same scan prescription.
5.5.2 Limitations
A limitation of the study is that the effects of different scan parameters, scan conditions and
scanner manufacturers could not be comprehensively studied due to scanner time constraints,
patient comfort concerns and the small patient sample size. This chapter illustrates our
preliminary findings and experiences with the first ten patients implanted with the Sirius
MRI markers. We are currently acquiring MRI images of more patients implanted with
the Sirius MRI markers to further optimize the pulse sequence and investigate if there
is any clinically significant difference of the DVH parameters between CT-only, CT-MRI
fusion-based, and MRI-only post-implant dosimetry.
Compared to the use of CT, a limitation of using MRI is that geometric distortion125
may introduce uncertainty in the reconstructed seed positions. Given the current quality
assurance methods to test MRI geometric distortion, gradient distortion correction techniques
as well as the small size of the prostate, the error of reconstructed seed positions due to
geometric distortion can be managed. However, care must be taken when investigating dose
distributions to critical structures far from the center on images with large field-of-view.
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Conversely, prostate geometrical distortion of another kind can be observed on post-implant
CT images due to edema and the inherent indistinct borders can cause the misrepresentation
of anatomy. Although current post-implant CT images provide absolute coordinates of
the seeds, we are also concerned with the relative distance to critical structures and the
distribution of seeds within the prostate volume, thus dose-volume-histograms are used
extensively. Methods for correcting geometric distortions evaluated in phantom do not
fully represent patient-induced distortions.125 Thus, the impact of geometric distortion on
dose-volume-histogram parameters of prostate implants can be illuminated in future studies.
Another limitation of this study is that the pulse sequence parameters were derived with
the emphasis on high marker signal at the expense of scan time, resulting in motion artifacts
when used in patients. The emphasis on high marker signal is to enable threshold-based
automated marker identification and seed extrapolation. However, for manual marker and
seed identification, if the Sirius MRI marker is not hyperintense and even isointense to the
prostatic stroma, the needle tracks still allow distinction between the Sirius MRI marker
and prostatic stroma.
The pulse sequence parameters that were derived based on phantom studies have two
main limitations, namely temperature and coil. Due to logistical reasons, the phantom was
scanned at room temperature instead of at body temperature. The Medrad endorectal coil
(Bayer Healthcare LLC, Whippany, NJ) is generally used for patient scans, but this coil
does not fit in the prostate phantom, hence the phantom images were acquired using an
8-channel torso coil (GE, Waukesha, WI) typically used for pelvic exams.
5.5.3 Current status
Since the initial experience in the first 10 patients implanted with Sirius MRI markers
described in this study, our institution has continued to optimize the post-implant MRI
protocol.
Kim et al.126 previously compared the inflatable coil (Medrad, as described in this
chapter) and a rigid endorectal coil (USA Instruments, Aurora, OH) and found that the
inflatable coil caused significantly greater prostate compression in the A/P direction and
widening in the R/L direction. To reduce prostate deformation, the current standard for the
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Figure 5.13: Axial, sagittal and coronal views of the prostate acquired with a rigid endorectal
coil show less prostate de formation.
coil to be used in the post-implant MRI protocol with Sirius MRI markers at our institution
is the Sentinelle endorectal coil (Invivo, Gainesville, FL), which is a rigid smaller-diameter
endorectal coil about the size of a TRUS probe. This coil is currently under investigation to
reduce prostate deformation while maintaining marker conspicuity (Figure 5.13).
5.5.4 Implications
Use of MRI instead of CT-MRI fusion for post-implant dosimetry can decrease the time and
costs required of patients and hospital staff. In clinics utilizing CT-MRI fusion, the use of
Sirius MRI markers alleviates the need for an extra CT scan to localize the seeds, thereby
eliminating additional ionizing radiation to the patient, reducing uncertainties caused by
imprecise registration from CT-MRI fusion, and improving the efficiency of the workflow.
In institutions currently only using CT for post-implant dosimetry, better prevention of
recurrence and prediction of side effects can improve the overall quality of life for patients,
thus offsetting the greater upfront financial cost and time to undergo an MRI exam instead
of a CT exam.
The advantages of using marker-based MRI-only post-implant dosimetry are easier
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identification of hyperintense markers compared to hypointense seeds, prevention of spacers
being incorrectly identified as seeds, and better distinction between needle tracks and blood
vessels.
Nevertheless, even with the use of the markers for MRI-based post-implant dosimetry,
the true dose distribution may vary between scans due to motion of the internal structures,
such as varying amounts of bladder/rectal displacements.108 This motion artifact can be
minimized by the use of glucagon to reduce bowel peristalsis, or by reducing the scanning
duration. Ultimately, the advantages of dedicated MRI-only post-implant evaluation are
superior soft tissue contrast, no extraneous radiation dose, image-acquisition flexibility and
possible integration of functional imaging.
In the next chapter, I present semi-automated marker-seed finding algorithms that could
facilitate better integration of the markers into busy brachytherapy clinics.
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6.1 Introduction
6.1.1 Seed Localization Algorithms on CT/CT-MRI Fusion Images
Many algorithms have been developed for different types of imaging modalities. On CT
images, the seeds are distinctly visible and many automated seed-localization algorithms for
CT images have been reported. On CT-MRI fusion images, seed localization is still mainly
performed on the hyperintense seeds visible on CT images.
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(a) Seed finder (b) Seed finder and manual corrections
Figure 6.1: Seed positions as localized by the (a) VariSeed seed finder tool and (b) after
manual corrections. Reprinted from M. De Brabandere, B. Al-Qaisieh, L. De Wever, K.
Haustermans, C. Kirisits, M. A. Moerland, R. Oyen, A. Rijnders, F. Van den Heuvel,
and F. A. Siebert. “CT- and MRI-based seed localization in postimplant evaluation after
prostate brachytherapy”. In: Brachytherapy 12.6 (2013), pp. 580–871 (license number:
3876110458254).
In a multi-institutional study, Bice et al.26 described seed localization by first counting
the number of seeds on anterior-posterior radiograph images or examining the implant
documentation to determine the expected number of seeds, then applying a semi-automated
nearest-neighbor approach to reduce the identified seeds to the expected number of seeds.
Brinkman et al.127 reported an automated algorithm on CT images using a workflow of
threshold and connected component analysis. Li et al.128 and Lee et al.129 also demonstrated
similar thresholding-based automated seed localization. Holupka et al.130,131 described seed
localization using Hough transforms. Tubic et al.132 reported automatic seed localization
before the generation of CT images, directly on the sinogram (the raw data plot with rays
on the x-axis and angles on the y-axis85).
Current brachytherapy TPS, such as VariSeed and MIM Symphony, have the seed
localization algorithm on CT images built-in to the graphic user interface. The TPS-
generated seeds positions usually require some manual corrections (Figure 6.1).
6.1.2 Seed Localization Algorithms on MRI Images
Dubois et al.70 described seed localization method similar to that of Bice et al.,26 that
is, by manually localizing the seeds on each slice, check abutting slices for any repeated
identification of the same seed, then reduce to the expected number of seeds.
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Lee et al. (2007)129 developed a semi-automated seed localization algorithm on MRI
images by examining Day 30 MRI images on six patients who received real-time MRI-guided
prostate implants. After cropping to the ROI, a manually-determined threshold was used to
remove bony structures and soft tissues, then connected component analysis was performed
until the specified number of seeds were identified. The authors reported a unanimous
100% seed identification rate in their 6-patient cohort. However, the pulse sequence used
to generate the MRI images used in this study was unclear, as the authors stated that
the work was an extension of MRI pulse sequence optimization efforts, citing the work of
Dubois et al..70 However, the MRI images used for algorithm development were of recipients
of real-time MRI-guided prostate implants (citation not provided). D’Amico et al.133 and
Cormack et al.134 demonstrated real-time MRI-guided prostate implants in a 0.5 T split-bore
interventional MR unit with images acquired using T1- and T2-weighted sequences.
Kuo et al.114 described a Laplacian of a Gaussian blob detection technique on images
acquired with an IRON prepulse and reported identification of 62 of 61 seeds (one false
positive) on phantom images.
Current brachytherapy TPS do not have the capability to automatically find seeds on
MRI images with the click of a button.
6.2 Purpose
Seed localization algorithms for MRI-based post-implant dosimetry based on Sirius MRI
markers have not been demonstrated. An asset of CT-based post-implant dosimetry is the
availability of automated seed localization tools that enable reproducible seed localization.27
Conversely, De Brabandere et al.27 reported greater interobserver variability of seed localiza-
tion on T1-weighted images compared to CT images as a result of differences in the observers’
interpretations of the seed voids exact locations, especially in the longitudinal direction.
Manual seed localization on MRI images, even with the use of Sirius MRI markers, is
time-consuming and not clinically-feasible for large volumes of patients. An automated seed
localization algorithm may increase the practicality of marker-based MRI-only post-implant
dosimetry.
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6.3 Methods
6.3.1 Data Collection
A multi-modality prostate phantom (Model 053-MM for ultrasound, CT and MRI; CIRS,
Norfolk, VA) was implanted with 66 Sirius MRI markers (C4 Imaging, Houston, TX) and
86 dummy seeds in stranded seed-marker combination using 20 needles. The phantom was
imaged using a 3.0 T MRI scanner (Discovery MR750; GE, Waukesha, WI) and an 8-channel
torso coil (GE, Waukesha, WI) with a 3D fast radiofrequency-spoiled gradient recalled
echo (FSPGR) sequence. The scan parameters used were: TR/TE = 8/3.6 ms, NEX =
8, FOV = 14 cm, BW = ±83.3 kHz, α = 14◦, 256× 256 (interpolated to 512× 512), and
frequency-encoding direction = anterior/posterior.
6.3.2 Marker-based Seed Localization Algorithm Workflows
The MRI images were processed using two strategies (Figure 6.2):
1. Non-template-based: The MRI image set was first preprocessed to obtain an ROI
of the filtered image. Then, a threshold was defined and applied to the image set to
obtain regions likely to contain markers. Next, connected component analysis was
performed to detect the Sirius MRI marker positions. Lastly, the seed positions were
extrapolated from the Sirius MRI marker positions.
2. Template-based: The MRI image set was first preprocessed to obtain an ROI of the
filtered image. Then, a threshold was defined and applied to the image set to obtain
regions likely to contain markers. Next, connected component analysis was performed
to detect the Sirius MRI marker positions. Then, instead of directly extrapolating
from the detected marker positions, the detected marker positions were registered to
the predicted marker positions. The final step then was extrapolating these registered
marker positions to the seed positions.
6.3.3 Image Processing
All image processing were performed using Matlab 8.1.0 (The Mathworks, Inc., Natick, MA).
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Figure 6.2: Marker-based seed-localization algorithm workflows based on two strategies:
(a) non-template-based, and (b) template-based. The difference between the two strategies
(highlighted in dark blue) is that pre-implant template information is used for registration
in the template-based strategy.
132
Chapter 6 Marker-based Seed Localization Algorithms
Preprocess The MRI images were first imported into the workspace. The ‘open’ filter,
consisting of ‘erode’ and ‘dilate’ operations, was used as the background. The background
was subtracted from the original image. The image was then cropped to a rectangular ROI.
To standardize the testing process, I set a fixed ROI that sufficiently covers the prostate
and includes all markers and seeds. In non-testing settings, the user would be prompted
to select a region-of-interest on the image. The filter was applied first before cropping to
the region-of-interest such that the structuring element could better sample the edges of
the region-of-interest. The downside of filter-then-crop as opposed to crop-then-filter is
computation time, but the computation time was not discernible. The pseudocode for the
preprocess function is provided in Algorithm 1.
Algorithm 1 Preprocess an MRI image set
procedure Preprocess(image path, number of slices)
Read in image set from path
(Rotate x,y coordinates of image due to Matlab flipping x,y axes)
Background ← Morphological open filter (Matlab built-in function)
Filtered image ← Image - Background
Define ROI containing prostate
Record pixels of filtered image within defined ROI
end procedure
Threshold For each slice in the image set, the image coordinates were recorded if the
image intensity at the location was greater than the set threshold. The pseudocode for the
preprocess function is provided in Algorithm 2.
Algorithm 2 Threshold an MRI image set
procedure Threshold(image intensities, threshold)
for all pixel intensities on each slice do
Record the row and column locations where the intensity > threshold
Record the slice location
end for
end procedure
Connected Component Analysis The limits that define the same marker were defined
in all 3 directions. All points were first set to be unique. For each point, if it was unique,
distances to all other points were calculated. Extra points were recorded as such and the
point was set to be not unique anymore. Then, for each unique point, the average of all
the extra points were recorded as the marker location. The image coordinate system was
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then converted to physical dimensions in cm. The pseudocode for the preprocess function is
provided in Algorithm 3.
Algorithm 3 Connected component analysis
procedure CCA(bright coordinates)
Initialize all bright coordinates to be unique markers
for all bright coordinates do
if a coordinate-in-question is a unique marker then
for all other coordinates do
if this-other-coordinate is also a unique marker then
Distance = | coordinate-in-question - this-other-coordinate |
if Distance < preset marker limits then
Extra coordinate ← this-other-coordinate
Record that coordinate-in-question is no longer unique
Record that this-other-coordinate is no longer unique
end if
end if
end for
if no extra points then
Store as a marker centroid
else
Calculate centroid from coordinate-in-question and extra coordinates
Store as a marker centroid
end if
end if
end for
end procedure
Extrapolate To find the unique strands given all the detected locations of the Sirius
MRI markers, k-means clustering was performed, which partitions n observations into k
clusters by minimizing the within-cluster sum-of-squares. To find markers belonging to
the same strand, the n observations are the marker locations while the k clusters are the
strand numbers. For each strand, the coordinates of the marker in the strand were recorded.
If only one marker was present in the strand, one seed was added above the marker and
another seed was added below the marker. For more than one marker in a strand, one seed
was added above the first marker, one seed was added after the last marker and seeds were
added in between the markers in the strand. The pseudocode for the preprocess function is
provided in Algorithm 4.
Registration For the template-based workflow, an additional registration step was taken
before extrapolation. Before each implant, a pre-implant plan is always generated to
determine the number and locations of the seeds and markers. A priori information from this
pre-implant plan can be taken for the registration purposes. From the pre-implant needle
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Algorithm 4 Extrapolation
procedure Extrapolation(detected marker coordinates, number of strands)
Perform k-means clustering using squared Euclidean x and y distances
for each strand do
Determine this strand’s markers x, y, z
if only one marker in this strand then
Top seed x, y ← marker x, y
Top seed z ← marker z - 0.5
Bottom seed x, y ← marker x, y
Bottom seed z ← marker z + 0.5
else
for each marker in strand do
if first marker then
Imaginary marker x, y ← marker x, y - (next marker x, y - marker x, y)
Top seed x, y ← (marker x, y + imaginary marker x, y) / 2
Top seed z ← marker z - 0.5
end if
if last marker then
Imaginary marker x, y ← marker x, y + (marker x, y - prev marker x, y)
Bottom seed x, y ← (marker x, y + imaginary marker x, y) / 2
Bottom seed z ← marker z + 0.5
else
if distance between next marker and this marker > expected then
Temp marker x, y, z ← (marker x, y, z + next marker x, y, z) / 2
Seed x, y, z ← (marker x, y, z + temp marker x, y, z) / 2
Next seed x, y, z ← (temp marker x, y, z + next marker x, y, z) / 2
else
Seed x, y, z ← (marker x, y, z + next marker x, y, z) / 2
end if
end if
end for
end if
Record this strand’s seeds x, y, z
end for
end procedure
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template, the number of needles, x, y and z (based on retraction) positions of the seeds and
markers were recorded, dependent on the loading pattern of each strand. The pseudocode
for the preprocess function is provided in Algorithm 5. Then, given all the detected marker
locations, k-means clustering was performed to find the unique strands. For each strand,
the detected/clustered strand indices were matched to the template strand indices using the
nearest neighbor method. For each strand, the registered marker positions were matched
to the detected marker positions. For strands with missing markers, a distance matrix was
built for each marker in the strand to determine which markers in the strand were visible to
enable the correct registration. Once the markers were detected, the seed positions were
determined from the marker positions by matching to the pre-implant needle template’s
defined strand loading pattern. The pseudocode for the preprocess function is provided in
Algorithm 6.
Algorithm 5 Get template information
procedure gettemplate
Input number of needles from needle template
Input retractions of each needle from needle template
Input alphabets of each needle from needle template
Input y template locations of each needle from needle template
Input number of seeds in each needle from needle template
Input number of markers in each needle from needle template
Number the alphabets according to alphabetical order
Convert the inputted alphabets to numeric indices of x
x← (x index - 1) / 2 (Subtract to start at 0 and divide to convert to cm)
y ← y index / 2
for each needle do
for each seed s in needle do
Record x, y
Record z ← retraction + s - 1
Record the needle number
if not last seed (place markers) then
Record x, y
Record z ← retraction + s - 0.5
Record number of seeds above this marker
Record number of seeds below this marker
end if
end for
end for
end procedure
Validation To validate the detected marker and seed positions, I manually identified the
marker and seed positions on the MRI images. The manually-identified positions were
treated as the ground truth. The limits for whether a marker was considered detected were
defined in all 3 directions. The distances between each detected marker/seed positions
136
Chapter 6 Marker-based Seed Localization Algorithms
Algorithm 6 Registration
procedure Registration(detected marker coordinates, template marker coordinates)
Calculate center-of-mass of template marker coordinates
Calculate center-of-mass of detected marker coordinates
Shift template marker positions to match detected marker positions
Perform k-means clustering using squared Euclidean x and y distances of detected markers
Record number of strands
Record template strand indices
for each strand do
Record shifted template strand centroids
end for
for each strand in template do
for each strand detected on image do
∆x← shifted template centroid x - detected centroid x
∆y ← shifted template centroid y - detected centroid y
Distance matrix =
√
∆x2 + ∆y2
end for
end for
for each strand do
Determine detected strand indices that correspond to template strand indices by finding the minimum
distances
end for
for each strand do
Extract shifted template positions
Extract detected marker positions
if template and detected marker match then
Registered marker positions ← detected marker positions
else
Calculate z shift to account for unmatching retraction
for each template marker position do
template marker position ← template marker position - z shift
end for
for each template marker positions do
for each detected marker position do
∆x,∆y,∆z ← template marker x, y, z - detected centroid x, y, z
Distance matrix =
√
∆x2 + ∆y2 + ∆z2
end for
end for
for each strand do
Matched marker index← detected marker index that correspond to template marker index by finding
the minimum distance
end for
for each matched marker do
for each next matched marker do
if matched marker index == next matched marker index and matched marker index not 0 then
if distance between template marker and detected matched marker < distance between next
template marker and detected matched marker then next matched marker index = 0
elsematched marker index = 0 (marker undetected on image cannot be matched to template-
predicted marker)
end if
end if
end for
end for
Check scenarios according to Algorithm 7
end if
Record registered marker coordinates of this strand
end for
for each strand do
if one marker in strand then
Add top and bottom seeds
else
Add seed before first marker
Add seeds in between markers
Add seed after last marker
end if
Record seed coordinates
end for
end procedure
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Algorithm 7 Check scenarios of detected and undetected markers
procedure CheckScenarios
for each marker in this strand do
if matched marker index not 0 (no markers undetected on image) then
marker x, y, z ← corresponding detected marker x, y, z
else
if undetected marker is not 1st or last marker then
if prev marker also undetected but next marker is detected then
marker x, y ← next marker x, y
marker z ← next marker z - 1
else if prev marker detected but next marker also undetected then
if there is a marker prev to the prev marker then
if previous-previous marker detected then
marker x, y ← prev marker x, y - (prev-prev marker x, y - prev marker x, y)
marker z ← prev marker z + 1
end if
else
marker x, y ← prev marker x, y
marker z ← next marker z + 1
end if
else
marker x, y, z ← (prev marker x, y, z + next marker x, y, z) / 2
end if
else if 1st marker undetected then
if 2nd marker also undetected but 3rd marker detected then
1st marker x, y ← 3rd marker x, y
1st marker z ← 3rd marker z - 2
else if second marker detected but 3rd marker also undetected then
1st marker x, y ← 2nd marker x, y
1st marker x, y ← 2nd marker z - 1
else(second and third markers detected)
1st marker x, y, z ← 2nd marker x, y, z - (3rd marker x, y, z - 2nd marker x, y, z)
end if
else if last marker undetected then
if 2nd-last marker also undetected but 3rd-last marker detected then
if there is a 4th-last marker then
if 4th-last marker is detected then
Last marker x, y ← 3rd-last marker x, y + 2× (3rd-last marker x, y - 4th-last marker x, y)
Last marker z ← 3rd-last marker z + 2
end if
else
Last marker x, y ← 3rd-last marker x, y
Last marker z ← 3rd-last marker z + 2
end if
else if 2nd-last marker detected but 3rd-last marker undetected then
Last marker x, y ← 2nd-last marker x, y
Last marker z ← 2nd-last marker z + 1
else(2nd-last and 3rd-last markers detected)
Last marker x, y, z ← 2nd-last marker x, y, z + (2nd-last marker x, y, z - 3rd-last marker x, y, z)
end if
end if
end if
end for
end procedure
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Algorithm 8 Validation of detected seed or marker locations
procedure Validation(detected centroids, manually-identified centroids)
Start with n = 0
for each detected centroid do
for each manually-identified centroids do
Distance ← | detected centroids - manually-identified centroids |
if distance < 3 mm in XY and 2 mm in Z then
n← n + 1
end if
end for
end for
True positive ← n
if Number detected - n > 0 then
False negative ← Number detected - n
else
False negative ← 0
end if
Calculate sensitivity according to Equation 6.1
Calculate precision according to Equation 6.2
Calculate F-score according to Equation 6.3
end procedure
and all the manually-identified marker/seed positions were calculated to determine the
number of markers/seeds that were truly detected by the algorithm, which is the number
of true positives (TP). The number of false positives (FP) is the number of truly detected
markers/seeds subtracted from the number of detected markers/seeds. The number of false
negatives (FN) is the number of detected markers/seeds subtracted from the number of
manually-identified markers/seeds. To determine the efficacy of the algorithm, sensitivity,
precision and the F-score (measure of accuracy) were then calculated.
Sensitivity =
TP
TP + FN
(6.1)
Precision =
TP
TP + FP
(6.2)
F-score =
2× Precision× Sensitivity
Precision + Sensitivity
(6.3)
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6.4 Results and Discussion
6.4.1 Performance
(a) Original (b) Flip
(c) Filter (d) Filtered and Cropped
Figure 6.3: The preprocessing function imported the (a) original images, (b) flipped the axes
due to Matlab axes definition, (c) applied a filter, then (d) cropped to the ROI containing
prostate.
The preprocess function can highlight the relevant pixels containing markers for further image
processing. Flipping the image axes to match Matlab’s image axes definition (Figure 6.3b)
did not affect marker/seed localization. This is because the definition of a coordinate system
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Figure 6.4: Regions of markers after thresholding.
is arbitrary within the prostate and the distance between markers/seeds were preserved
in this workflow. Mulitple filter types are available on Matlab. The erosion filter (Figure
6.3c), as well as its corresponding structuring element type and size, were selected based
on trial-and-error. The defined ROI eliminated extraneous signal from outside the prostate
(Figure 6.3d), so that subsequent functions (such as connected component analysis) would
not have to process these extraneous signal and can be more efficient.
Figure 6.4 depicts “blobs”, or regions on the image that most likely contain the markers.
Since each marker span over multiple pixels in all 3 directions, each marker had multiple
coordinates defined, forming a “blob”.
By finding the centroids of the “blobs” of markers, the marker positions can be better
defined (Figure 6.5). Multiple studies described in Sections 6.1.1 and 6.1.2 adopt the
connected component analysis for seed-finding, that is, by identifying the pixels containing
seeds on the images and image slices, then defining seed locations as the centroids of these
pixels. For instance, Dubois et al.70 and Bice et al.26 referred to the connected component
analysis as “nearest-neighbor approach” for processing their manually-identified pixels as
seeds, while Kuo et al.114 referred to this connected component analysis as “blob-detection
technique” for finding the seeds on MRI images with the IRON prepulse.
Instead of an arbitrary image coordinate system, the marker and seed locations are
mapped out in physical dimensions based on pixel sizes (Figure 6.6).
To be able to properly extrapolate the seed locations from the marker locations, the
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Figure 6.5: Connected component analysis find the marker centroids.
Figure 6.6: Marker centroids in real dimensions.
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Figure 6.7: k-means clustering was performed to find individual strands (identified with
light blue star).
Figure 6.8: Seeds positions (red) extrapolated from marker positions (blue).
markers need to be grouped by their strands. k-means clustering was performed to identify
the individual strands (Figure 6.7).
By knowing the strand information of the markers, the seeds can be extrapolated. For
instance, if a strand only have two markers, one seed would be extrapolated in between the
two markers, and one seed would be extrapolated from the other ends of the two markers as
the first and last seeds. For strands with only one marker, first and last seeds are placed
directly above the marker. Figure 6.8 depicts the seed and marker positions obtained using
the non-template-based seed localization algorithm.
To check whether the seed and marker locations identified on Figure 6.8 were accurate,
they must be compared to true seed and marker locations. The true seed and marker
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Figure 6.9: Validated marker (blue) and seed (red) positions generated by manual identifica-
tion.
locations were defined based on seed and marker locations manually-identified directly on
the MRI images. Figure 6.9 shows the validated marker and seed positions.
When overlaying the marker and seed positions identified using the non-template-based
algorithm over the validated marker and seed positions, we can readily identify false negatives
(Figure 6.10). This is due to some marker intensities not meeting the threshold and thus
those markers were not identified. The misidentification of markers propagates to seeds not
being able to be extrapolated.
A way to overcome the seed false negatives is to incorporate the information about the
expected number of markers and seeds in each strand. This information can be obtained
from the pre-implant plan that is always generated for each implant. The marker and seed
positions obtained from the pre-implant needle template are modeled as perfectly parallel
strands (Figure 6.11). The pre-implant marker and seed configurations are currently explicitly
recorded based on the needle template (Figure 1.5). However, with the incorporation of the
template-based seed localization algorithm into a TPS, the TPS would already have the
pre-implant seed and marker configurations in its environment, thus obviating the need to
explicitly define marker and seed configurations.
Since the coordinate system is arbitrary, and only the distances between markers/seeds
are definitive, the centers-of-mass of the pre-implant coordinate system and the detected
marker coordinate system are matched (Figure 6.12).
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Figure 6.10: Non-template-based localization of (a, b) markers and (c, d) seeds.
Figure 6.11: Preimplant marker and seed positions generated from pre-implant needle
template.
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(a) Not shifted (3D) (b) Not shifted (2D)
(c) Shifted (3D) (d) Shifted (2D)
Figure 6.12: Coordinates shifted to match center-of-masses.
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(a) k-means clusters from images (b) Clusters from pre-implant template
Figure 6.13: To obtain the information on the seed and marker configurations, (a) the
strands identified on the images are matched to the corresponding (b) pre-implant needle
strands.
The k-means clustering algorithm generated clusters and numbered the strands arbitrarily
(Figure 6.13a). The pre-implant template numbers the strands consecutively from left-to-
right, top-to-bottom (Figure 6.13b). Therefore, to obtain the information on the seed and
marker configurations, the strand numbers were matched 6.13).
With the pre-implant template information, the template-based algorithm was able to
determine the marker locations based on the expected marker configuration in a strand,
even when the markers had low signal intensity on MRI images. Compared to the non-
template-based algorithm, the template-based algorithm was able to identify more markers
(Figure 6.14).
Lastly, as was done with the non-template-based algorithm, the seed locations were
extrapolated from the marker locations for the template-based algorithm as well (Figure
6.15).
Figure 6.16 depicts the template-based algorithm’s identified seed and marker locations
compared to the validated seed and marker locations. Since curvature information is not
available from the pre-implant template, curvature could not be accounted for the last strand
when some markers in that strand had low signal intensity on MRI images.
The non-template-based and template-based algorithm localized seed and marker po-
sitions are shown in Figure 6.10 and 6.16. The sensitivity, precision and F-score acquired
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Figure 6.14: Non-template-based (filled circles) versus template-based (circles) marker and
seed localization.
Figure 6.15: Template-based algorithm identified seed (red) and marker (blue) locations.
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Figure 6.16: Seed (red) and marker (blue) positions identified by the template-based
algorithm (circles) compared to seed and marker positions that were manually-identified
(asterisks).
Table 6.1: Sensitivity, precision and F-score acquired for the non-template-based and
template-based seed-identification algorithms.
Non-template-based Template-based
Markers
Sensitivity 0.9242 0.9242
Precision 1.0000 1.0000
F-score 0.9606 0.9606
Seeds
Sensitivity 0.9651 0.9884
Precision 1.0000 0.9884
F-score 0.9822 0.9884
for the non-template-based and template-based seed-identification algorithms are listed in
Table 6.1. The non-template-based seed identification algorithm was prone to FN, as seed
extrapolation would not occur if the adjacent marker was not identified. The template-based
seed-identification algorithm was able to identify seeds even when the adjacent markers were
not visible.
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6.5 Conclusion
6.5.1 Summary
The seed-finding algorithms are flexible for localizing seeds at the ends of the strand. For the
extrapolation-based method, the seeds can be detected if the adjacent markers were detected,
but would not otherwise. For the template-based method, the seeds can be detected even if
the adjacent markers were not detected.
6.5.2 Limitations
A limitation of the seed-localization algorithms outlined in this chapter is that they do not
handle seed migration. For the template-based method, even when there is no marker or
seed at a location, a marker or seed will be assigned at that location based on the template.
Another limitation of this study is that not all possible combinations of each image
processing component were tested. For instance, for preprocessing, various image filters
could be used and the order in which they are applied could be varied.
Moreover, the sensitivity and precision were set at certain limits that may under- or
over-account for the number of markers and seeds detected. More stringent limits could be
set which would result in lower sensitivity and precision.
Furthermore, the algorithms were tested on phantom images. Seed localization on patient
images in the clinical scenario would be more challenging, especially with strands that may
be more curved due to the manifestation and recession of edema distorting the strands.
The marker-based seed-localization algorithms cannot handle curved strands as the seed
locations are extrapolated from Sirius MRI marker locations. A vessel enhancement filter135
may potentially be used to handle strand curvature. Further optimization and validation for
the marker-based seed algorithms on clinical images is needed before routine clinical use.
6.5.3 Implications
The seed-finding algorithm could potentially be incorporated into the MIM Symphony TPS
to ensure a smooth post-implant dosimetry workflow. The algorithm for seed-identification
based on Sirius MRI markers has been developed. These Sirius MRI markers could potentially
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enable more widespread use of MRI for post-implant dosimetry with further testing and
optimization.
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7.1 Overall Summary
The Sirius MRI markers may spur the use of MRI for post-implant dosimetry by helping
overcome the barrier of seed localization on MRI images. To enable MRI-only post-implant
dosimetry using Sirius MRI markers, a TPS that will allow for marker-based post-implant
dosimetry is first needed. The MIM Symphony TPS was identified as a viable alternative to
the widely-used VariSeed TPS. In Chapter 6, the calculations of DVH and other dosimetric
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parameters by the two TPS were compared and found to be clinically-comparable.
The intrinsic relaxation characteristics of the C4 contrast agent encapsulated in the Sirius
MRI markers were evaluated. The C4 contrast agent’s spin-lattice and spin-spin relaxivities
for different field strengths, orientations and temperatures have been documented in Chapter
3.
From the relaxation characteristics of the C4 contrast agent, a suitable pulse sequence
that enhances the Sirius MRI markers was identified. In Chapter4, the effects on the Sirius
MRI markers’ SNR, scan time and resolution due to variations in user-adjustable pulse
sequence parameters, such as α, NEX, BW, FOV, ∆z, and Nx × Ny were identified in a
prostate phantom. Subsequently, the initial experience visualizing Sirius MRI markers in
patients using the pulse sequence parameter ranges determined in phantom, as well as the
unique challenges of using Sirius MRI markers in the clinical setting, were described in
Chapter 5.
To enable higher efficiency in clinics, the observer-dependent manual seed localization
on MRI images needs to be automated. Two approaches of marker-based seed localization
algorithms, with and without pre-implant template information, were presented in Chapter
6.
7.2 Future Directions
The marker-based seed localization algorithm could be improved. Line detection methods
may be incorporated into the algorithm to better handle curved strands. In the future, when
more datasets (MRI images of the markers and the marker/seed locations) are available,
sophisticated machine learning techniques may be explored for enhanced marker and seed
localization. Instead of in-house algorithms operating external to the post-implant dosimetry
workflow, the algorithms may be incorporated into the brachytherapy TPS for greater
efficiency.
Future clinical trials for the Sirius MRI marker will further illuminate any clinical chal-
lenges. Depending on the pulse sequence used and time lapsed since the brachytherapy
procedure, the Sirius MRI marker’s signal may be obscured or confused with other hyper-
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intense sources, such as adipose tissue, cysts, hemorrhage, or edema from infections.72 A
potential study is to evaluate the post-implant MRI images for image quality, seed and
marker visualization, geometric distortion and image blur using a subjective scoring system,
similar to the method adopted by Schieda et al..123
Efficacy and feasibility comparisons can also be made against other MRI-only post-
implant dosimetric assessment methods that do not require the use of the Sirius MRI marker,
such as the techniques69,70,73,114–122 described in Section 5.1.4.
Another possible study is the impact of the Sirius MRI markers by comparing DVH
parameters generated from CT images, MRI images, and CT-MRI fusion images, given the
MRI protocol described in this study. More importantly, the efficacy of using these DVH
parameters for the prediction of acute and late effects of LDR prostate brachytherapy could
be studied.
There may also be exciting implications for recurrence prediction and management using
multiparametric MRI to assess tumor response to treating prostate cancer using prostate
implants.136 Multiparametric MRI combines anatomic imaging (T2-weighted imaging) with
functional information from MR spectroscopy (MRS), diffusion-weighted imaging (DWI)
and dynamic contrast-enhanced MRI (DCE-MRI). Although T2-weighted images have
limited utility due to radiation-induced morphologic transformations such as inflammation
and fibrosis, MRS, DWI and DCE-MRI may be used for detection of local recurrence.137
Pathologic Gleason scores has been correlated with high MRS ratios.138–140 Cornud et al.141
reported the relationship between apparent diffusion coefficient from DWI to Gleason score.
Future studies can look into the potential of correlating the dose distribution within the
prostate on MRI images with additional information obtained using multiparametric MRI
to guide the evaluation of the presence of clinically significant disease and the differentiation
between recurrent disease or radiation necrosis.124 While PSA elevations can be due to local
or distant recurrence or even false-positives, MRI with endorectal coil and MRS findings
can better correlate with biopsy findings of local tumor extent and aggressiveness, compared
to PSA findings.66,142
The incorporation of time-of-flight MR angiography for the visualization of the internal
pudendal arteries to improve the management of erectile dysfunction5 can enhance marker-
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based MRI-only post-implant dosimetry. Gillan et al.5 had established the use of time-of-flight
MR angiography for Day 30 evaluation with CT-MRI fusion, and further research can be done
with MRI-only post-implant dosimetric evaluation to assess the dose-response relationship.
Apart from post-implant dosimetry, the Sirius MRI marker may be used during real-time
MRI-guided prostate brachytherapy for rapid intraoperative seed localization. D’Amico et
al.133 demonstrated real-time MRI-guided prostate brachytherapy using a 0.5 T intraoperative
MRI, whereby each insertion the seed locations and DVH were calculated and adjustments
can be made intraoperatively whenever necessary.
Another potential indication for the Sirius MRI marker is to serve as a fiducial marker
for a variety of other image guided radiation therapy purposes. The use of both permanent
and temporary implantable fiducial markers is standard in many disease sites. For example,
fiducial markers are placed in the prostate for daily image-guided radiation treatment, in
the cervix for localization and treatment planning, in the breast for tumor localization prior
to lumpectomy, and in the lung for tumor tracking during radiation therapy.
7.3 Future Implications
MRI-based post-implant dosimetry may reduce inconsistencies in target delineation and
subsequent reporting of DVH parameters. With more accurate DVH parameters, we can
better quantify the radiation dose to cancerous and various surrounding normal tissue, such
that a more accurate picture of acute and late effects of brachytherapy can be depicted. The
dose-response relationship for critical organs and subsequent toxicity can be studied in a
more meaningful manner, such that we can better manage the dose delivered to the prostate
and surrounding critical structures in the future.
The ultimate objective of the LDR prostate brachytherapy treatment is to have high
tumor control probability (TCP) and low normal tissue complication probability (NTCP),
hence the current long-term goal would be to correlate the dose received by the prostate
and adjacent critical structures to clinical outcomes. Accurate seed positions coupled with
clear anatomical delineation on MRI images allows for accurate characterization of the dose
distribution and lowers interobserver variation. This enables better prediction and prevention
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of acute or late effects, as well as better prediction of underdosed areas in the prostate for
enhanced tumor control. Sirius MRI markers may enable MRI-based post-implant dosimetry,
and have exciting potential for biologically-based treatment plan evaluation and optimization.
Biological evaluation of treatment plans using TCP and NTCP models may improve clinical
decision making.143 The more accurate dose and volume metrics provided by MRI-based
post-implant dosimetry, combined with other considerations (such as age, performance status
and patient-reported outcomes) may be used to build more predictive TCP and NTCP
models.
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